Quarterlytics / Industrials / Conglomerates / Ocean Bio-Chem

Ocean Bio-Chem

obci · NASDAQ Industrials
Claim this profile
Ticker obci
Exchange NASDAQ
Sector Industrials
Industry Conglomerates
Employees 201-500
← All annual reports
FY2012 Annual Report · Ocean Bio-Chem
Sign in to download
Loading PDF…
40YEARS

973 -   2 0 1

1

3

As you have probably noted from the cover of our annual report, Ocean Bio-Chem/ 
Star brite® is celebrating it’s 40th Anniversary this year.  Since 1973, our Company 
has accomplished many milestones. Some are highlighted below.

4041 SW 47th Avenue  •  Fort Lauderdale, Florida 33314 • Tel:(954) 587-6280  •  (800) 327-8583  •  Fax:(954) 587-2813
WWW.OCEANBIOCHEM.COM  •  WWW.STARBRITE.COM  •  WWW.STARTRON.COM

2012 ANNUAL REPORT LETTER TO SHAREHOLDERS

Fellow Shareholders:

We ended 2012 on a very high note with record fourth quarter sales, gross margins and operating profits. For the 
year 2012, the slight reduction in sales was mainly attributable to our largest customer implementing an inventory 
reduction program of 15%, as we have reported. We fully anticipate that in 2013 sales to this customer will increase, 
as their lower inventory levels have been achieved. Your company is stronger today as we have broadened our sales 
efforts to new markets and increased sales to existing customers in our core marine market in order to help lessen the 
impact of the actions of any one customer.

In order to maximize sales to new customers and distribution channels, we have increased our advertising and 
marketing expenditures to create additional consumer awareness and brand recognition in these new markets. In 
2012, we also introduced an exciting consumer rebate program for our Star Tron® product group. Early indications 
indicate that it will be very successful program, educating the end consumer to the attributes and benefits of Star 
Tron®. This is a long-term strategic program designed to expand our customer base. These initiatives contributed to 
the reduced earnings for the year 2012. Marketing and advertising programs take time to produce results and we 
expect excellent returns in the relatively near future as well as in the long term.  

The Company had several major accomplishments in 2012. Examples include new distribution in three major 
national automobile chains as well as expansion into a major hardware/home goods chain in the northern part of 
the United States. We confidently and optimistically look forward to continued expansion of our customer base for 
all products in 2013 and beyond.

In order to maintain and improve our capital assets, in 2012 we continued to upgrade property, plant and 
equipment in our Kinpak manufacturing facility, investing an additional $770 thousand dollars. The total net book 
value of our property, plant and equipment is $5.3 million dollars.  We estimate the current replacement cost of our 
property, plant and equipment to be well in excess of $20 million dollars.

Ocean Bio-Chem’s 2013 outlook and potential remain positive as we continue to develop new products and explore 
new markets. We are optimistic that 2013 will be another successful year for the Company, building on the gains 
achieved in 2012 and earlier. We are currently working on a group of new products to be introduced in 2014 
that will utilize our patented chlorine dioxide delivery system. The new product is a liquid disinfectant that will be 
named Xtrem-A-Cide P®. This patented product is a broad-spectrum disinfectant that has EPA approval for use as 
a sanitizer, virucide, tuberculocide, fungicide, algaecide, slimicide and deodorizer. The applications for this product 
are immense, ranging from consumer use to industrial. 

In closing, I would like to express my appreciation to all of the Ocean Bio-Chem. Inc., employees for their continued 
dedication and efforts in achieving the milestones and successes over the past year. We are also very grateful for the 
support of all of our customers, suppliers and shareholders.

Peter G. Dornau
President and Chief Executive Officer

UNITED STATES 
SECURITIES AND EXCHANGE COMMISSION 
Washington, D.C. 20549 

FORM 10-K 

           ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 

           TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 

For the fiscal year ended December 31, 2012 

Commission File Number 000-11102 

OCEAN BIO-CHEM, INC. 
(Exact name of registrant as specified in its charter) 

Florida 
(State or other jurisdiction of incorporation or 
organization) 

59-1564329 

(I.R.S. Employer Identification No.) 

4041 SW 47 AVENUE 
FORT LAUDERDALE, FLORIDA  33314 
(Address of principal executive offices) 

954-587-6280 
(Registrant’s telephone number, including area code) 

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class 
Common Stock, $0.01 par value 

Name of each exchange on which registered 
The NASDAQ Stock Market 

Securities registered pursuant to Section 12(g) of the Act: 
None 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes      No   

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes    No  

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during 
the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for 
the past 90 days.    Yes      No   

Indicate by check  mark  whether  registrant has submitted electronically and posted on its corporate Website, if  any every Interactive Data File required to be 
submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 (or for such shorter period that the registrant was required to submit and 
post such files).    Yes      No   

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of 
registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any  amendment to this Form   
10-K.       

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the 
definitions of “large accelerated filer,” “accelerated filer” and smaller reporting company” in Rule 12b-2 of the Exchange Act. 

Large accelerated filer     
Non-accelerated filer     

Accelerated filer     
Smaller reporting company  

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes      No   

The  aggregate  market  value  of  the  Common  Stock  held  by  non-affiliates  of  the  registrant  at  June  29,  2012  was  $6,460,514.  For  purposes  of  making  this 
computation only, all executive officers, directors and beneficial owners of more than five percent of the registrant's Common Stock are deemed to be affiliates. 

At April 1, 2013, 8,398,385 shares of the registrant’s voting Common Stock were outstanding.   

DOCUMENTS INCORPORATED BY REFERENCE 

Portions of the registrant's definitive proxy statement, which will be filed not later than April 30, 2013, are incorporated by reference in Part III of this report. 

 
 
 
  
  
  
  
 
  
   
   
 
  
  
 
   
   
  
  
  
  
 
 
 
  
  
  
 
  
  
  
   
OCEAN BIO-CHEM, INC. AND SUBSIDIARIES 

TABLE OF CONTENTS 

Business  

PART I 
Item 1. 
Item 1A.  Risk Factors  
Item 1B.  Unresolved Staff Comments  
Item 2. 
Item 3. 
Item 4 

Properties 
Legal Proceedings  
Mine Safety Disclosures  

Market for Registrant’s Common Equity,  Related Stockholder Matters and Issuer Purchases of Equity Securities  
Selected Financial Data  
Management’s Discussion and Analysis of Financial Condition and Results of Operations  

PART II 
Item 5. 
Item 6. 
Item 7. 
Item 7A.  Quantitative and Qualitative Disclosures about Market Risk  
Financial Statements and Supplementary Data  
Item 8. 
Item 9. 
Changes in and Disagreements With Accountants on Accounting and Financial Disclosure  
Item 9A.  Controls and Procedures 
Item 9B.  Other information  

PART III 
Item 10.  Directors, Executive Officers and Corporate Governance  
Item 11. 
Item 12. 
Item 13. 
Item 14. 

Executive Compensation  
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters  
Certain Relationships and Related Transactions, and Director Independence  
Principal Accounting Fees and Services  

PART IV 
Item 15. 

Exhibits, Financial Statements Schedules  
Signatures  

Forward-looking Statements: 

Page 

1-3 
4-5 
5 
5 
5 
5 

5-6 
6 
6-10 
10 
10 
10 
10 
11 

11 
11 
11 
11 
11 

12-13 
14 

Certain  statements  contained  in  this  Annual  Report  on  Form  10-K,  including  without  limitation,  sufficiency  of  funds  provided  through 
operations  and  existing  sources  of  financing  to  satisfy  our  cash  requirements,  constitute  forward-looking  statements.  For  this  purpose,  any 
statements contained in this report that are not statements  of historical fact  may be  deemed forward-looking  statements.  Without limiting the 
generality of the foregoing, words such as "believe," "may," "will," "expect," "anticipate," "intend," or "could," including  the negative or other 
variations  thereof  or  comparable  terminology,  are  intended  to  identify  forward-looking  statements.  These  statements  involve  known  and 
unknown risks, uncertainties and other factors which may cause actual results to be materially different from those expressed or implied by such 
forward-looking statements.  Factors that may affect these results include, but are not limited to, the highly competitive nature of our industry, 
increasing  oil  and  related  petrochemical  and  petroleum  prices,  reliance  on  certain  key  customers,  changes  in  consumer  demand  for  marine, 
recreational vehicle and automotive products, advertising and promotional efforts, and exposure to market risks relating to changes in interest 
rates and foreign exchange rates. 

   
 
   
  
 
 
   
   
   
   
   
   
 
   
 
   
   
 
   
 
   
   
 
   
 
   
  
 
 
   
   
 
   
 
 
Item 1.    Business 

General: 

PART I 

We  are  principally  engaged  in  the  manufacturing,  marketing  and  distribution  of  a  broad  line  of  appearance,  performance,  and  maintenance 
products for the marine, automotive, power sports, recreational vehicle and outdoor power equipment markets, under the Star brite®, Star Tron®, 
and  other  trademarks  within  the  United States  of  America  and  Canada.  In  addition,  we  produce  private  label  formulations  of  many  of  our 
products for various customers and provide custom blending and packaging services for these and other products.  Unless, the context indicates 
otherwise, we sometimes refer to Ocean Bio-Chem, Inc. and its consolidated subsidiaries as “the Company," "we" or "our.” 

Ocean Bio-Chem, Inc. was incorporated in 1973 under the laws of the state of Florida.  In 1981, we purchased, from Peter G. Dornau and Arthur 
Spector,  the  co-founders  of  the  Company,  rights  to  the  Star brite®  trademark  and  related  products  for  the  United States  and  Canada.  Mr. 
Dornau,  our  Chairman,  President  and  Chief  Executive  Officer,  has  retained  rights  to  these  assets  with  respect  to  all  other  geographic 
areas.  Accordingly, products that we manufacture that are sold outside of the United States and Canada are purchased from us and distributed by 
two companies owned by Mr. Dornau.  Net sales to the two companies in 2012 totaled approximately $1,487,000, or 4.8% of our net sales.  See 
Note 8 to the consolidated financial statements included in this report for additional information. 

On May 10, 2010, the  Company announced the  formation of OdorStar Technology  LLC (“OdorStar”), a joint venture between the Company 
and BBL  Distributors,  LLC.  OdorStar  owns  patents  that  relate  to  a  formula  and  delivery  system,  for  use  with  products  containing  chlorine 
dioxide,  designed  to  safely  prevent  and  eliminate  all  types  of  odors  relating  to  mold,  mildew,  and  other  sources  of  unpleasant  odors.  The 
Company  and  BBL  Distributors  LLC  share  equally  in  profits  or  losses  from  OdorStar.   Because  the  Company  manages  OdorStar,  it  has 
consolidated OdorStar in its financial statements. 

Products: 

The products that we manufacture and market include the following: 

Marine:  Our marine line consists of polishes, cleaners, protectants and waxes under the Star brite® brand name, enzyme fuel treatment under the 
Star Tron®  brand  name,  and  private  label  products.  The  marine  line  also  includes  motor  oils,  boat  washes,  vinyl  cleaners,  protectants,  teak 
cleaners,  teak  oils,  bilge  cleaners,  hull  cleaners,  silicone  sealants,  polyurethane  sealants,  polysulfide  sealants,  gasket  materials,  lubricants, 
antifouling  additives  and  anti-freeze  coolants.  In  addition,  we  manufacture  a  line  of  brushes,  poles,  tie-downs  and  other  related  marine 
accessories. 

Automotive:  We manufacture a line of automotive products under the Star brite® and Star Tron® brand names  The automotive line includes fuel 
treatments  for  both  gas  and  diesel  engines,  motor  oils,  greases  and  related  items.  In  addition,  we  produce  anti-freeze  and  windshield  washes 
under the Star brite® brand and under private labels for customers.  We also produce automotive polishes, cleaners and other appearance items. 

Recreational Vehicle/Power Sports:  We  also  market  Star Tron® fuel treatment to the recreational vehicle  market,  including snow  mobiles, all 
terrain vehicles and motorcycles.  Power sports enthusiasts have found Star Tron® a viable solution to a number of problems associated with E-
10  fuel,  which  contains  ethanol.  Other  recreational  vehicle/power  sports  products  include  cleaners,  polishes,  detergents,  fabric  cleaners  and 
protectors,  silicone  sealants,  waterproofers,  gasket  materials,  degreasers,  vinyl  cleaners  and  protectors,  toilet  treatment  fluids  and  anti-freeze 
coolants. 

Outdoor Power Equipment/ Lawn & Garden: We market Star Tron® as a viable solution to help rectify a number of operating engine problems in 
commercial  lawn  equipment  and  other  home  and  garden  power  equipment  associated  with  using  E-10  fuel,  which  is  fuel  containing  10% 
ethanol.   

Contract  Filling  and  Blow  Molded  Bottles:  We  blend  and  package  a  variety  of  chemical  formulations  to  our  customers’  specifications.  In 
addition, we manufacture for sale to various customers assorted styles of both PVC and HDPE blow molded bottles. 

Mold/Mildew Odor Control:  We manufacture and market a variety of products under the Star brite® name that help prevent and eliminate all 
types of  mold,  mildew, and other unpleasant odors, through OdorStar’s patented delivery system.  Our odor control products are effective  for 
homes, automobiles, boats and recreational vehicles. 

Although our products are utilized for different types of vehicles and boats, and for home care, we believe our operations constitute one industry 
segment. 

1 

  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
   
Manufacturing:  We  produce  the  majority  of  our  products  at  the  manufacturing  facilities  of  our  subsidiary,  Kinpak,  Inc.  ("Kinpak"),  in 
Montgomery, Alabama.  In addition, we contract with various unaffiliated companies located in the northeastern and mid-western areas of the 
country to manufacture our other products, which are manufactured to our specifications using our provided formulas.  Each third party packager 
enters into a confidentiality agreement with us. 

We  purchase  raw  materials  from  a  wide  variety  of  suppliers;  all  raw  materials  used  in  manufacturing  are  readily  available  from  alternative 
sources.  We design our own  packaging and supply our outside  manufacturers  with the appropriate design or packaging.  We believe that our 
internal manufacturing capacity and our arrangements with our current outside manufacturers are adequate for our present needs. 

In  the  event  that  arrangements  with  any  third-party  manufacturer  are  discontinued,  we  believe  that  we  will  be  able  to  locate  substitute 
manufacturing facilities without a substantial adverse effect on our manufacturing and distribution. 

Marketing and Significant Customers:  Our products are sold through national retailers such as Wal-Mart, Tractor Supply,West Marine, and 
Bass  Pro  Shops.  We  also  sell  to  national  and  regional  distributors  that  sell  our  products  to  specialized  retail  outlets.  Currently  we  have  two 
customers  to  whom  sales  exceeded  10%  of  consolidated  net  revenues  for  the  year  ended  December  31,  2012.  Sales  to  these  two  customers 
represented approximately 37% of consolidated net sales.  Sales to our five largest unaffiliated customers for the year ended December 31, 2012, 
amounted to approximately 49% of our consolidated net sales,  and at December 31, 2012, outstanding accounts receivable balances  from our 
five largest unaffiliated customers aggregated approximately 23% of our consolidated accounts receivable. 

We  market  our  products  through  internal  salesmen  and  approximately  40  sales  representatives  who  work  on  an  independent  contractor 
commission  basis.  Our  personnel  also  participate  in  sales  presentations  and  trade  shows.  In  addition,  we  market  our  brands  and  products 
through advertising campaigns in national magazines, television, newspapers and product catalogs.  Our products are distributed primarily from 
Kinpak’s  manufacturing and  distribution  facility in Montgomery,  Alabama.  Since 2008,  we have participated in a vendor managed inventory 
program with one major customer. 

Backlog,  Seasonality,  and  Selling  Terms:  We  had  no  significant  backlog  of  orders  at  December  31,  2012.  We  do  not  give  customers  the 
absolute right to return product.  The majority of our products is non-seasonal and is sold throughout the year.  Normal trade terms offered to 
credit  customers  range  from  30  to  60  days.  However,  at  times  we  offer  extended  payment  terms  or  discount  arrangements  as  purchasing 
incentives to customers.  These initiatives do not materially affect customary margins. 

Competition: 

Competition with respect to our principal product lines is described below:  The principal elements of competition affecting all of our product 
lines are brand recognition, price, service and the ability to deliver products on a timely basis. 

Marine:  We have several national and regional competitors in the marine marketplace.  We do not believe that any competitor or small group of 
competitors hold a dominant market share.  We believe that we can increase or maintain our market share through expenditures directed to our 
present methods of advertising and distribution. 

Automotive:  There  are  a  large  number of companies, both national and regional, that compete  with  us.  Many are  more established and have 
greater financial resources than we do.  While our market share is small, the total market size is substantial.  We believe that we have established 
a reasonable market share through our present methods of advertising and distribution, considering the large size of this market. 

Recreational Vehicle/Power Sports:  We compete with national and regional competitors.  We do not believe that any competitor or small group 
of  competitors  hold  a  dominant  market  share.  We  believe  that  we  can  increase  or  maintain  our  market  share  by  utilizing  similar  methods  to 
those we use in the marine market. 

Outdoor Power Equipment/Lawn  & Garden:  We  compete  with several established national and regional competitors.  We  do not believe that 
any competitor or small group of competitors hold a dominant market share.  We have attempted to make inroads in this market by emphasizing 
Star Tron®’s unique formulation and by increasing our advertising and attendance at trade shows. 

Trademarks:  We  have  obtained registered trademarks  for Star brite®, Star Tron® and other trade names  used on our products.  We view our 
trademarks as significant assets because they provide product recognition.  We believe that our intellectual property is protected, but we cannot 
assure that our intellectual property rights can be successfully asserted in the future or will not be invalidated, circumvented or challenged. 

Patents:  In 2010, the Company acquired an interest in patents held by OdorStar.  The patents relate to a delivery system, for use with products 
containing  chlorine  dioxide,  designed  to  safely  prevent  and  eliminate  all  types  of  odors  relating  to  mold,  mildew,  and  other  unpleasant 
odors.  The patents expire in 2022. 

2 

   
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
New Product Development:  We continue to develop specialized products for the marine, automotive, recreational vehicle/power sports and 
outdoor power equipment/lawn and garden markets.  Expenditures for new product development have not been significant and are charged to 
operations in the year incurred. 

Personnel:  At December 31, 2012, we had 117 full-time employees.  The following table provides information regarding personnel working for 
the Company and its subsidiaries at December 31, 2012: 

Location 

Fort Lauderdale, Florida 
Fort Lauderdale, Florida 
Montgomery, Alabama 

Description 

    Administrative 
    Manufacturing and distribution 
    Manufacturing and distribution 

    Full-time Employees 
28 
7 
82 
117 

3 

  
 
 
   
   
   
   
   
       
   
  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Item 1A.  Risk Factors 

If we do not compete effectively, our business will suffer. 

We  confront  aggressive  competition  in  the  sale  of  our  products.  In  each  of  the  markets  in  which  we  sell  our  products,  we  compete  with  a 
number  of  national  and  regional  competitors.  Competition  in  the  automotive  market  is  particularly  intense,  with  many  national  and  regional 
companies marketing competitive products.  Many of our competitors in the automotive market are more established and have greater financial 
resources  than  we  do.  Our  inability  to  successfully  compete  in  our  principal  markets  would  have  a  material  adverse  effect  on  our  financial 
condition, results of operations and cash flows. 

Economic conditions can adversely affect our business. 

We  are  subject  to  risks  arising  from  adverse  changes  in  general  domestic  and  global  economic  conditions,  including  recession  or  economic 
slowdown and disruption of credit markets, which may impair the ability of our customers to satisfy obligations due to us.  In addition, adverse 
economic conditions in recent years have adversely affected discretionary spending, which can have an indirect adverse effect on our product 
lines,  particularly  those  directed  to  the  marine  and  recreational  vehicle  markets.  A  continued  economic  slowdown  or  a decline  in  economic 
conditions could have a material adverse effect on our financial condition, results of operations and cash flows. 

Failure to effectively utilize or successfully assert intellectual property rights could materially adversely affect our competitiveness. 

We rely on trademarks and trade names in connection with our products, the most significant of which are Star brite® and Star Tron®.  OdorStar 
also  owns  patents  we  consider  important  to  our  business.  We  rely  on  trademark,  trade  secret,  patent  and  copyright  laws  to  protect  our 
intellectual  property  rights.  We  cannot  assure  that  these  intellectual  property  rights  will  be  effectively  utilized  or,  if  necessary,  successfully 
asserted.  There is a risk that we will not be able to obtain and perfect our own intellectual property rights, or, where appropriate, license from 
others intellectual property rights necessary to support new product introductions.  Our intellectual property rights, and any additional rights we 
may obtain in the future, may be invalidated, circumvented or challenged in the future.  Our failure to perfect or successfully assert intellectual 
property rights could make us less competitive and could have a material adverse effect on our financial condition, results of operations and cash 
flows. 

Environmental matters may cause potential liability risks. 

We must comply with various environmental laws and regulations in connection with our operations, including those relating to the handling and 
disposal of hazardous wastes and the remediation of contamination associated with the use and disposal of hazardous substances.  A release of 
such substances due to accident or intentional act could result in substantial liability to governmental authorities or to third parties.  In addition, 
we  are  subject  to  reporting  requirements  with  respect  to  certain  materials  we  use  in  our  manufacturing  operations.  In  January  2011,  Kinpak, 
which owns our manufacturing facility in Montgomery, Alabama, became subject to a consent agreement and final order with the United States 
Environmental  Protection  Agency  relating  to  its  alleged  failure  to  complete  and  submit  certain  required  forms  with  respect  to  toxic  and 
hazardous chemicals used at its facilities.  Under the consent agreement and final order, Kinpak paid a civil penalty of $110,000.  It is possible 
that  we  could  become  subject  to  additional  environmental  liabilities  in  the  future  that  could  have  a  material  adverse  effect  on  our  financial 
condition, results of operations and cash flows. 

Our variable rate indebtedness exposes us to risks related to interest rate fluctuation. 

The  Company  has  a  revolving  line  of  credit  with  a  variable  interest  rate.  At  December  31,  2012,  the  Company  did  not  have  any  borrowings 
outstanding  under  the  revolving  line  of  credit.  However,  during  2012  the  highest  amount  outstanding  under  the  revolving  line  of  credit  was 
$1,700,000.  Interest  on  the  revolving  line  of  credit  is  payable  at  the  30  day  LIBOR  rate  plus  1.74%  per  annum  (unless  the  Company’s  debt 
service  coverage  ratio,  as  defined  in  the  credit  agreement,  falls  below  2.0  to  1,  in  which  case  the  additional  percentage  will  be  2.75%  per 
annum).  In no event will the interest rate be less than 2.0% per annum.  If interest rates were to increase significantly, our financial condition, 
results of operations and cash flows could be materially adversely affected. 

Our Chairman, President and Chief Executive Officer is a majority shareholder who controls us, and his interest may conflict with or 
differ from the Company's interests. 

Peter G. Dornau,  our  Chairman,  President  and  Chief  Executive  Officer,  owns  approximately  55%  of  our  Common  Stock.  As  a  result, 
Mr. Dornau has the power to elect all of our directors and effectively has the ability to prevent any transaction that requires the approval of our 
Board of Directors and our shareholders.   Products that we manufacture and that are sold outside of the United States and Canada are purchased 
from  us  and  distributed  by  two  companies  owned  by  Mr. Dornau,  which  we  refer  to  as  the  “affiliated  companies.”  Sales  to  the  affiliated 
companies  aggregated  approximately  $1,487,000  and  $1,764,000  during  the  years  ended  December 31,  2012  and  2011,  respectively.  An 
affiliated company owns the rights to the Star brite® and Star Tron® trademarks and related products outside of the United States and Canada. 

4 

  
 
 
  
 
  
 
 
 
 
 
  
  
  
   
 
   
In addition, we provided administrative services to the affiliated companies for fees aggregating approximately $335,000 and  $332,000 during 
the years ended December 31, 2012 and 2011, respectively.  While the terms of the sales to the affiliated companies differed from the terms of 
sale to other customers, the affiliated companies bear their own warehousing, distribution, advertising, selling and marketing costs, as well as 
their own freight charges (we pay freight charges in connection with sales to our domestic customers on all but small orders).  Moreover, we do 
not pay sales commissions with respect to products sold to the affiliated companies.  As a result, we believe our profit margins with respect to 
sales to the affiliated companies are similar to the profit margins we realize with respect to sales to our larger domestic customers.  Management 
believes that the sales to the affiliated companies did not involve more than normal credit risk or present other unfavorable features.  We have 
entered into other transactions with entities owned by Mr. Dornau.  See Note 8 to the consolidated financial statements included in this report for 
additional information. 

Trading in our Common Stock has been limited, and our stock price could potentially be subject to substantial fluctuations. 

Our  common  stock  is  listed  on  the  NASDAQ  Capital  Market,  but  trading  in  our  stock  has  been  limited.  Our  stock  price  could  be  affected 
substantially by a relatively modest volume of transactions. 

Item 1B. Unresolved Staff Comments 

Not applicable. 

Item 2. Properties 

Our executive offices and one of our manufacturing facilities is located in Fort  Lauderdale, Florida and are leased from an entity controlled by 
our  Chairman,  President  and  Chief  Executive  Officer.  The  lease  covers  approximately  12,700  square  feet  of  office,  manufacturing,  and 
warehouse space.  See Note 9 to the consolidated financial statements included in this report for additional information. 

We  own  Kinpak’s  Alabama  facility,  which  currently  contains  approximately  300,000  square  feet  of  office,  plant  and  warehouse  space  on  20 
acres of land.  We also lease a 1.5 acre docking facility on the Alabama River, located approximately eleven miles from these facilities.   

Item 3.    Legal Proceedings 

Not applicable. 

Item 4.    Mine Safety Disclosures 

Not applicable. 

Item 5.    Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 

Our common stock is traded on the NASDAQ Capital Market under the symbol OBCI.  A summary of the high and low sales prices during each 
quarter of 2012 and 2011 is presented below. 

PART II 

2012 

2011 

High 
Low 

High 
Low 

1st Qtr. 

2nd Qtr. 

3rd Qtr. 

4th Qtr. 

   $ 
   $ 

   $ 
   $ 

2.78       $ 
2.01       $ 

3.93       $ 
1.80       $ 

2.59       $ 
1.83       $ 

3.56       $ 
2.16       $ 

2.59       $ 
1.76       $ 

4.40       $ 
1.98       $ 

2.50    
1.81    

2.68    
1.68    

We  had  144  record  holders  of  our  Common  Stock  at  December  31,  2012.  We  believe  that  there  are  approximately  900  additional  beneficial 
holders of our Common Stock, based on information obtained from our transfer agent and from broker-dealers that hold shares on behalf of their 
clients. 

The Company has not paid any cash dividends since its incorporation.  The Company does not currently intend to pay any cash dividends, but 
instead will utilize available cash to fund operations. 

5 

  
 
 
  
 
 
  
 
 
 
 
 
 
  
  
 
   
   
      
      
      
   
   
   
     
        
        
        
   
   
   
   
      
            
            
            
      
   
 
  
   
  
 
 
 
 
Item 6.   Selected Financial Data 

Not applicable. 

Item 7.    Management’s Discussion and Analysis of Financial Condition and Results of Operations 

The following discussion should be read in conjunction with our consolidated financial statements contained herein as Item 8. 

Overview: 

We  are  principally  engaged  in  the  manufacturing,  marketing  and  distribution  of  a  broad  line  of  appearance,  performance,  and  maintenance 
products for the marine, automotive, power sports, recreational vehicle and outdoor power equipment markets, under the Star brite® and other 
trademarks  within the  United States of  America and Canada.  In addition,  we produce private  label  formulations of  many of our products for 
various  customers  and  provide  custom  blending  and  packaging  services  for  these  and  other  products.  We  sell  our  products  through  national 
retailers and to national and regional distributors who, in turn, sell our products to specialized retail outlets. 

Critical accounting estimates: 

The  preparation  of  consolidated  financial  statements  in  accordance  with  accounting  principles  generally  accepted  in  the  United  States  of 
America  requires  management  to  make  estimates  and  assumptions  that  affect  the  reported  amounts  of  assets  and  liabilities  and  disclosure  of 
contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting 
period.  Actual results could differ from those estimates and assumptions. 

We  have  identified  the  following  as  critical  accounting  estimates,  which  are  defined  as  those  that  are  reflective  of  significant  judgments  and 
uncertainties, are the most pervasive and important to the presentation of our financial condition and results of operations  and could potentially 
result in materially different results under different assumptions and conditions. 

Revenue recognition and collectability of accounts receivable 

Revenue from product sales is recognized when persuasive evidence of a contract exists, the sales price is fixed and determinable, the title of 
goods pass to the customer, and collectability of the related receivable is probable.  With respect to a customer for whom the Company manages 
the inventory at the customer's location, revenue is recognized when the products are sold to a third party.  In the ordinary course of business, we 
grant non-interest bearing trade credit to our customers on normal credit terms.  In an effort to reduce our credit risk, we perform ongoing credit 
evaluations of our customers and adjust credit limits based upon payment history and customers’ creditworthiness, as determined by our review 
of  their  current  credit  information.  We  monitor  collections  and  payments  from  our  customers  and  maintain  a  provision  for  estimated  credit 
losses based upon our historical experience, specific customer collection issues and reviews of agings of trade receivables based on contractual 
terms.  We  generally  do  not  require  collateral  on  trade  accounts  receivable.  We  maintain  an  allowance  for  doubtful  accounts  based  on  our 
historical  collection  experience  and  expected  collectability  of  the  accounts  receivable,  considering  the  period  an  account  is  outstanding,  the 
financial  position  of  the  customer  and  information  provided  by  credit  rating  services.   The  adequacy  of  this  allowance  is  reviewed  each 
reporting period and adjusted as necessary.  Our allowance for doubtful accounts was approximately $73,000 and $75,000 at December 31, 2012 
and 2011, respectively, which was approximately 2.4% and 2.8%, respectively,  of gross accounts receivable.  If the financial condition of our 
customers were to deteriorate, resulting in an impairment of their ability to make payments, or if unexpected events or significant future changes 
in trends were to occur, additional allowances may be required, resulting in increased bad debt expense. 

Inventories 

Inventories primarily are composed of raw materials and finished goods and are stated at the lower of cost or market, using the first-in, first-out 
method.  We maintain a reserve for slow moving and obsolete inventory to reduce the carrying value of our inventories to reflect the diminution 
of value resulting from product obsolescence, damage or other issues affecting marketability by an amount equal to the difference between the 
cost  of  the  inventory  and  its  estimated  market  value.  The  adequacy  of  this  reserve  is  reviewed  each  reporting  period  and  adjusted  as 
necessary.  We regularly compare inventory quantities on hand against historical usage or forecasts related to specific items in order to evaluate 
obsolescence and excessive quantities.  In assessing historical usage, we also qualitatively assess business trends to evaluate the reasonableness 
of using historical information as an estimate of future usage.  A complete physical count of the inventory is conducted annually. 

Our slow moving and obsolete inventory reserve was $271,994 and $276,703 at December 31, 2012 and December 31, 2011, respectively. 

6 

 
   
  
 
 
 
 
 
 
 
 
 
 
 
 
  
   
 
 
 
 
 
 
 
Income taxes 

Income  taxes  are  accounted  for  under  the  asset  and  liability  method.  Under  this  method,  deferred  tax  assets  and  liabilities  are  recognized  to 
reflect  the  future  tax  consequences  attributable  to  the  differences  between  the  financial  statement  carrying  amounts  of  existing  assets  and 
liabilities  and  their  respective  tax  bases.  Deferred  tax  assets  and  liabilities  are  measured  using  enacted  tax  rates  expected  to  apply  to  taxable 
income  in  the  years  in  which  the  differences  are  expected  to  be  recovered  or  settled.  The  temporary  differences  are  attributable  to  differing 
methods of financial statement and income tax depreciation and reserves for trade accounts receivable and inventories. 

The likelihood of a material change in the Company's expected realization of deferred tax assets is dependent on, among other factors, future 
taxable income and settlements with tax authorities.  While management believes that its judgments and interpretations regarding income taxes 
are  appropriate,  significant  differences  in  actual  experience  may  require  future  adjustments  to  our  tax  assets  and  liabilities,  which  could  be 
material. 

We  are  also  required  to  assess  the  realizability  of  our  deferred  tax  assets.  We  evaluate  positive  and  negative  evidence  and  use  judgments 
regarding  past  and  future  events,  including  operating  results  and  available  tax  planning  strategies  that  could  be  implemented  to  realize  the 
deferred tax assets.  Based on this assessment, we determine when it is more likely than not that all or some portion of our deferred tax assets 
may not be realized, in which case we would be required to apply a valuation allowance to offset our deferred tax assets in an amount equal to 
future tax benefits that may not be realized.  We currently do not apply a valuation allowance to our deferred tax assets.  However, if facts and 
circumstances change in the future, valuation allowances may be required. 

Significant judgment is required in determining income tax provisions and in evaluating tax positions.  We establish  additional provisions  for 
income  taxes  when,  despite  the  belief  that  tax  positions  are  fully  supportable,  there  remain  certain  positions  that  do  not  meet  the  minimum 
probability threshold, which is a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority.  In 
the  normal  course  of  business,  we  and  our  subsidiaries  are  examined  by  various  federal  and  state  tax  authorities.  We  regularly  assess  the 
potential outcomes of these examinations and any future examinations for the current or prior years in determining the adequacy of our provision 
for income taxes.  We adjust the income tax provision, the current tax liability and deferred taxes in any period in which facts that give rise to an 
adjustment become known.  The ultimate outcomes of the examinations of our income tax returns could result in increases or decreases to our 
recorded tax liabilities, which could affect our financial results. 

Trademarks, trade names and patents - We acquired the rights to the Star brite® trademark and related products for the United States and Canada 
in conjunction with our initial public offering during March 1981 for $880,000.  The cost of these intangible assets was amortized on a straight-
line  basis  over  an  estimated  useful  life  of  40  years  through  December  31,  2001.  Effective  January  1,  2002  and  pursuant  to  Statement  of 
Financial  Accounting  Standards  No.  142,  "Goodwill  and  Other  Intangible  Assets"  (now  codified  in  Financial  Accounting  Standards  Board 
Accounting Standards Codification Topic 350, "Intangibles  - Goodwill and Other"), we determined that these intangible assets have indefinite 
lives and therefore, we no longer recognize amortization expense.  In addition, our 50% owned joint venture, OdorStar Technology, LLC, owns 
patents we use in our business.  The Company amortizes these patents over their remaining life on a straight line basis.  We review the carrying 
values of the trademarks and patents periodically for possible impairment.  Our impairment review is based on a discounted cash flow approach 
that requires significant judgment with respect to unit volume, revenue and expense growth rates, and the selection of an appropriate discount 
rate.  Management  uses  estimates  based  on  expected  trends  in  making  these  assumptions.  All  impairment  charges  would  be  recorded  for  the 
difference between the carrying value and the net present value of estimated future cash flows, which represents the estimated fair value of the 
asset.  Management  uses  its  judgment  in  assessing  whether  assets  may  have  become  impaired  between  annual  valuations.  Indicators  such  as 
unexpected  adverse  economic  factors,  unanticipated  technological  change,  distribution  losses,  competitive  activities  and  acts  by  governments 
and courts may indicate that an asset has become impaired. 

7 

 
  
 
 
 
 
 
  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Results of Operations: 

Net  sales  were  approximately  $31,039,000  in  2012  compared  to  $31,681,000  in  2011,  a  decrease  of  $642,000  or  2.0%.  The  sales  decrease 
reflects a decline in sales to one of our largest customers, which engaged in an inventory reduction program in 2012.  The customers’ inventory 
reduction program is not expected to continue in 2013.  This sales decrease was partially offset by sales to new customers and increased sales to 
other established customers.  Net sales also reflected continued growth of our enzyme fuel treatment product, Star Tron®, into the retail markets 
to which our products are directed.   

Cost  of  goods  sold  and  gross  profit  –  Cost  of  goods  sold  during  2012  decreased  approximately  $585,000  or  2.8%,  to  approximately 
$20,412,000 from approximately $20,997,000 in 2011.  The decrease was principally due to the decrease in sales. 

Our  gross  profit  percentage  (gross  profit  as  a  percentage  of  net  sales)  increased  approximately  0.5%,  from  33.7%  in  2011  to  34.2%  in 
2012.  This increase primarily was a result of improved product sales mix and a reduction of cost of goods sold.  The $57,000 decrease in gross 
profit reflects lower net sales, somewhat mitigated by the increase in gross profit percentage. 

Advertising  and  promotion  expense  was  approximately  $2,418,000  in  2012,  an  increase  of  approximately  $438,000  or  22.1%  from 
approximately $1,980,000 in 2011.  As a percentage of net sales, advertising and promotion expense increased from 6.2% in 2011 to 7.8% in 
2012.  The  increase  in  advertising  expenditures  was  designed  to  support  the  expansion  of  Star Tron®  products  into  new  markets,  including 
automotive, power sports, motorcycle, small engine and outdoor power equipment markets .  We sponsored several television programs targeted 
to potential customers for our products and purchased print advertisements in several  national  magazines  targeted to automotive, boating and 
engine  maintenance  and  repair  enthusiasts,  as  well  as  in  specific  industry  magazines.  In  addition,  we  increased  expenditures  for  customer 
cooperative advertising allowances to promote our Star Tron® and Star brite® products in catalogs and sales promotion flyers. 

Selling  and  administrative  expenses  increased  by  about  $136,000  or  2.7%,  from  approximately  $4,990,000  in  2011  to  approximately 
$5,126,000  in  2012.  The  increase  is  principally  due  to  an  increase  in  sales-related  expenses  mainly  increased  staffing  and  related  expenses 
including travel and entertainment expenses.  As a percentage of net sales, selling and administrative expenses increased from 15.8% in 2011 to 
16.5% in 2012. 

Interest expense decreased approximately $52,000 to $98,000 in 2012, compared to $150,000 in 2011.  The decrease principally reflects  the 
reduction in our short-term and long-term indebtedness during 2012.  In addition, the reduction reflects reduced financing costs resulting from 
the July 2011 refinancing of both our short term borrowing and long term debt at lower interest rates. 

Operating income – As a result of the foregoing, operating income decreased to approximately $3,082,000 in 2012, compared to approximately 
$3,714,000 in 2011, a decrease of $632,000 or 17.0%. 

Income  taxes – We had a tax expense of approximately $1,055,000 in 2012 or 35.3% of pretax income, compared to $1,280,000 in 2011 or 
35.4% of pretax income.  For additional information, see Note 7 to the consolidated financial statements. 

Net  Income  and  Net  income  attributable  to  Ocean  Bio-Chem,  Inc. As  a  result  of  the  items  described  above,  net  income  decreased 
approximately  17.2%  or  approximately  $401,000  to  $1,934,000  from  $2,335,000  in  2011.  Net  income  attributable  to  Ocean  Bio-Chem,  Inc. 
(excluding the loss attributable to non-controlling interests)  was approximately $1,962,000 in 2012, a decrease of approximately $431,000 or 
18% from approximately $2,393,000 in 2011. 

Liquidity and Capital Resources: 

Our  cash  balance  was  approximately  $1,508,000  at  December  31,  2012  compared  to  approximately  $585,000  at  December  31,  2011.  At 
December 31, 2012 there were no borrowings under our revolving line of credit compared to $850,000 outstanding at December 31, 2011. 

Cash provided by operating activities for the year ended December 31, 2012 was approximately $2,775,000 compared to about $621,000 for the 
year ended December 31, 2011.  The increase in cash provided from operations is primarily due to the reduction in inventories of approximately 
$376,000 in 2012 as compared to the increase in inventories of approximately $1,849,000 in 2011.  In 2011, management increased inventory 
levels of petroleum based products in anticipation of rising oil prices in early 2012. 

Cash used in investing activities for the year ended December 31, 2012 was approximately $771,000 compared to $435,000 in 2011.  In 2012 we 
continued  to  upgrade  and  replace  older  less  efficient  equipment  in  our  Kinpak  manufacturing  facility  and  made  capital  improvements  to  our 
principal executive offices. 

8 

 
 
  
 
 
  
  
 
 
  
  
 
  
 
 
   
 
 
 
 
 
Cash used in financing activities for the year ended December 31, 2012 was approximately $1,081,000 compared to $215,000 for the year ended 
December 31, 2011.  The increase in cash used in financing activities in 2012 is due to net repayments on our line of credit of $850,000 in 2012 
compared to net borrowings of $850,000 in 2011.  In addition, in 2011 we paid the entire balance of approximately $472,000 on a related party 
note held by our Chairman, President and Chief Executive Officer, as described in Note 8 to the consolidated financial statements included in 
this report.  These increases were partially offset by the lower net reduction of approximately $400,000 in long-term debt in 2012 compared to 
the net reduction of approximately $658,000 in 2011.  We also received approximately $169,000 from the exercise of stock options in 2012 
compared to approximately $65,000 in 2011. 

Net trade accounts receivable aggregated approximately $2,931,000 at December 31, 2012 and $2,563,000 at December 31, 2011, an increase of 
14.4%.  This increase in accounts receivable is due to increased sales in December 2012.  

Inventories  were  approximately  $9,257,000  and  $9,628,000  at  December  31,  2012  and  2011,  respectively,  representing  a  decrease  of 
approximately $371,000 or 3.9% in 2012.  The higher levels of 2011 inventories compared to 2012 levels reflect management's 2011 decision to 
increase inventory levels of petroleum-based products in anticipation of rising oil prices. 

On July 6, 2011, we, together with our subsidiary, Kinpak Inc. (“Kinpak”), entered into a Credit Agreement with Regions Bank (and, pursuant to 
an Equipment Finance Addendum to the Credit Agreement, Regions Equipment Finance Corporation (“REFCO”)) under which (a) our revolving 
line of credit with Regions Bank was renewed, and (b) REFCO provided a new term loan in the amount of $2,430,000, the proceeds of which 
were used to pay the Kinpak’s remaining lease obligations in connection with the previously outstanding 2002 Series of Industrial Development 
Revenue Bonds issued by the City of Montgomery, Alabama (the “2002 Bonds”).  The 2002 Bonds were used to fund the expansion of Kinpak’s 
facilities and acquisition of related equipment. 

Under  the  term  loan,  we  pay  principal,  together  with  interest  at  the  fixed  rate  of  3.54%  per  annum,  in  72  consecutive  monthly  payments  of 
$37,511  over  the  six  year  period  beginning  on  August  6,  2011,  with  the  final  payment  due  on  July  6,  2017.  In  the  event  our  debt  service 
coverage ratio falls below 2.0 to 1, interest on the term loan will increase by 1.01% per annum.  For the year ended December 31, 2012, our debt 
service coverage ratio exceeded 6.0 to 1. 

The  Credit  Agreement  defines  “debt  service  coverage  ratio“  as  meaning  net  profit  plus  taxes,  interest,  depreciation,  amortization  and  rent 
expense  divided  by  debt  service  plus  interest  and  lease/rent  expense.  The  Credit  Agreement  contains  various  covenants,  including  financial 
covenants requiring a minimum debt coverage ratio of 1.75 to 1.00, tested on a rolling four-quarter basis, and a maximum debt to capitalization 
ratio  (funded  debt  divided  by  the  sum  of  total  net  worth  and  funded  debt)  of  0.75  to  1,  tested  quarterly.  At  December 31, 2012,  we  were  in 
compliance with these covenants. 

Under the renewed revolving line of credit, we may borrow up to the lesser of (i) $6 million and (ii) a borrowing base equal to 80% of eligible 
accounts receivable plus 50% of eligible inventory.  Interest on the revolving line of credit is payable at the 30 day LIBOR rate plus 1.74% per 
annum (unless our debt service coverage ratio falls below 2.0 to 1, in which case the additional percentage  will be 2.75% per annum).  In no 
event will the interest rate be less than 2.0% per annum.  Outstanding amounts under the revolving line of credit are payable on demand.  If no 
demand  is  made,  we  may  repay  and  reborrow  funds  from  time  to  time.  Interest  payments  are  made  in  monthly  installments  on  outstanding 
average balances with all outstanding principal and interest payable on July 6, 2014.  At December 31, 2012 there were no borrowings under our 
revolving line of credit. 

Our obligations under the Credit Agreement are secured by our accounts receivable and inventory, as well as real property and equipment at the 
Kinpak’s Montgomery, Alabama facility. 

In addition to the revolving line of credit and term loan, we have obtained financing through capital leases for both manufacturing and office 
equipment, totaling approximately $37,600 and $62,400 at December 31, 2012 and December 31, 2011, respectively. 

Our sales in the Canadian market are subject to currency fluctuations relating to the Canadian dollar.  We do not engage in currency hedging and 
address  currency  risk  as  a  pricing  issue.  In  the  year  ended  December  31,  2012,  we  recorded  approximately  $6,000  in  foreign  currency 
translation adjustments (increasing shareholders equity by $6,000). 

During the past few years, we have introduced a number of new products.  At times, new product introductions have required us to increase our 
overall inventory and have resulted in lower inventory turnover rates.  The effects of reduced inventory turnover have not been material to our 
overall operations.  We  believe that all required capital to maintain such increases  will continue to be provided by operations and our current 
financing arrangements. 

Many of the raw materials that we use in the manufacturing process are petroleum or chemical based and commodity chemicals that are subject 
to fluctuating prices.  The nature of our business does not enable us to pass through the price increases to our national retailers and distributors, 
as promptly as we experience increases in raw material costs.  This may, at times, adversely affect our margins. 

9 

 
   
  
 
 
 
 
 
 
  
 
 
 
 
 
   
 
At December 31, 2012 and through the date of this report, we did not and do not have any material commitments for capital expenditures, nor do 
we have any other present commitment that is likely to result in our liquidity increasing or decreasing in any material way. 

We believe that funds provided through operations and our existing sources of financing will be sufficient to satisfy our cash requirements over 
at least the next twelve months. 

Item 7A. Quantitative and Qualitative Disclosure about Market Risk 

Not applicable. 

Item 8.    Financial Statements and Supplementary Data 

The audited financial statements of the Company required pursuant to this Item 8 are included in a separate section commencing on page F-1 and 
are incorporated herein by reference. 

Item 9.    Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 

Not applicable. 

Item 9A.  Controls and Procedures: 

Evaluation of Disclosure Controls and Procedures.  The Company’s management, with the participation of the Company’s Chief Executive 
Officer and Chief Financial Officer, evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-
15(e)  and  15d-15(e)  under  the  Securities  Exchange  Act  of  1934,  as  amended  (the  "Exchange  Act")  at  the  end  of  the  period  covered  by  this 
report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and 
procedures as of the end of the period covered by this report are effective to provide reasonable assurance that the information required to be 
disclosed by the Company in reports filed under the Exchange Act are (i) recorded, processed, summarized and reported within  the time periods 
specified in the Securities and Exchange Commission's rules and forms, and (ii) accumulated and communicated to the Company’s management, 
including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding the disclosure. 

Change in Internal Controls over Financial Reporting.  No change in internal control over financial reporting (as defined in Rule 13a-15(f) 
under  the  Exchange  Act)  occurred  during  the  Company’s  most  recent  fiscal  quarter  that  has  materially  affected,  or  is  reasonably  likely  to 
materially affect, the Company’s internal control over financial reporting. 

Management’s Annual Report on Internal Control over Financial Reporting 

Management of Ocean Bio-Chem, Inc. is responsible for establishing and maintaining adequate internal control over financial reporting. Internal 
control  over  financial  reporting  is  a  process  designed  to  provide  reasonable  assurance  regarding  the  reliability  of  financial  reporting  and  the 
preparation  of  financial  statements  for  external  purposes  in  accordance  with  generally  accepted  accounting  principles.  A  company’s  internal 
control  over  financial  reporting  includes  those  policies  and  procedures  that pertain  to  the  maintenance  of  records  that,  in  reasonable  detail, 
accurately and fairly reflect the  transactions and dispositions of the assets of the company; provide reasonable assurance that transactions are 
recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts 
and  expenditures  of  the  company  are  being  made  only  in  accordance  with  authorizations  of  management  and  directors  of  the  company; 
and provide  reasonable  assurance  regarding  prevention  or  timely  detection  of  unauthorized  acquisition,  use,  or  disposition  of  the  company’s 
assets that could have a material effect on the financial statements. 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any 
evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that 
the degree of compliance with the policies or procedures may deteriorate. 

Management  evaluated  the  Company’s  internal  control  over  financial  reporting  as  of  December 31,  2012.  In  making  this  assessment, 
management used the framework established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations 
of  the  Treadway  Commission  (COSO).  As  a  result  of  this  assessment  and  based  on  the  criteria  in  the  COSO  framework,  management  has 
concluded that, as of December 31, 2012, the Company’s internal control over financial reporting was effective. 

10 

   
  
 
 
 
 
 
 
 
 
 
  
 
 
  
  
 
 
 
 
 
 
 
 
 
Item 9B.  Other Information 

Not applicable. 

Item 10.  Directors, Executive Officers and Corporate Governance 

PART III 

Information  required  by  this  item  is  incorporated  by  reference  to  the  Company's  definitive  proxy  statement,  which  will  be  filed  with  the 
Commission no later than 120 days after the close of the fiscal year covered by this report. 

Item 11.  Executive Compensation 

Information  required  by  this  item  is  incorporated  by  reference  to  the  Company's  definitive  proxy  statement,  which  will  be  filed  with  the 
Commission no later than 120 days after the close of the fiscal year covered by this report. 

Item 12.  Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters 

Information  required  by  this  item  is  incorporated  by  reference  to  the  Company's  definitive  proxy  statement,  which  will  be  filed  with  the 
Commission no later than 120 days after the close of the fiscal year covered by this report. 

Item 13.  Certain Relationships and Related Transactions, and Director Independence 

Information  required  by  this  item  is  incorporated  by  reference  to  the  Company's  definitive  proxy  statement,  which  will  be  filed  with  the 
Commission no later than 120 days after the close of the fiscal year covered by this report. 

Item 14.  Principal Accounting Fees and Services 

Information  required  by  this  item  is  incorporated  by  reference  to  the  Company's  definitive  proxy  statement,  which  will  be  filed  with  the 
Commission no later than 120 days after the close of the fiscal year covered by this report. 

11 

   
  
 
 
 
 
 
 
 
  
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Item 15.  Exhibits, Financial Statements, Schedules and Reports Filed on Form 8K 

(a) 

Financial Statements – See the Index to Consolidated Financial Statements on page F-1. 

PART IV 

(b) 

Exhibits: 

Exhibit   
No.    

3.1.1 

    Articles of Incorporation and amendments through May 20, 1994 (incorporated by reference to Exhibit 3.1 to the Company’s Annual 

Report on Form 10-K for the year ended December 31, 2010). 

*3.1.2      Articles of Amendment to the Articles of Incorporation, as filed on June 13, 2012. 
3.2 

    Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the 

Securities and Exchange Commission on December 5, 2011). 

†10.1      Ocean Bio-Chem, Inc. Omnibus Equity Compensation Plan (incorporated by reference to Exhibit 99.1 to the Company’s Registration 

Statement on Form S-8 (file no. 333-174659), filed with the Securities and Exchange Commission on June 2, 2011). 

10.2 

    Credit Agreement, dated July 6, 2011, among the Company, Kinpak, Inc. and Regions Bank (the “Credit Agreement”) (incorporated 

by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2011). 

10.3 

10.4 

10.5 

    Equipment Finance Addendum, dated July 6, 2011, among the  Company, Kinpak, Inc. and Regions Equipment Finance Corporation 
(incorporated  by  reference  to  Exhibit  10.1  to  the  Company’s  Quarterly  Report  on  Form  10-Q  for  the  quarter  ended  September 30, 
2011). 

    Promissory Note, dated July 6, 2011, issued by the Company to Regions Bank in connection with the revolving line of credit under the 
Credit Agreement (incorporated by reference to Exhibit 99.3 to the Company’s Current Report on Form 8-K, filed with the Securities 
and Exchange Commission on July 12, 2011). 

    Promissory  Note,  dated  July  6,  2011,  issued  by  the  Company  and  Kinpak,  Inc.  to  Regions  Equipment  Finance  Corporation  in 
connection  with  the  term  loan  under  the  Credit  Agreement  (incorporated  by  reference  to  Exhibit  99.4  to  the  Company’s  Current 
Report on Form 8-K, filed with the Securities and Exchange Commission on July 12, 2011).  

†10.6      Ocean  Bio-Chem,  Inc.  2002  Non-Qualified  Stock  Option  Plan,  as  amended  (incorporated  by  reference  to  Exhibit  99.2  to  the 
Company’s Registration Statement on Form S-8, filed with the Securities and Exchange Commission on August 12, 2011). 
†10.7      Ocean Bio-Chem, Inc. 2008 Incentive Stock Option Plan, as amended (incorporated by reference to Exhibit 99.4 to the  Company’s 

Registration Statement on Form S-8, filed with the Securities and Exchange Commission on August 12, 2011). 

†10.8      Ocean  Bio-Chem,  Inc.  2008  Non-Qualified  Stock  Option  Plan,  as  amended  (incorporated  by  reference  to  Exhibit  99.5  to  the 
Company’s Registration Statement on Form S-8, filed with the Securities and Exchange Commission on August 12, 2011). 
†10.9      Ocean Bio-Chem, Inc. Form of Stock Option granted to Peter G. Dornau (incorporated by reference to Exhibit 99.6 to the Company’s 

Registration Statement on Form S-8, filed with the Securities and Exchange Commission on August 12, 2011). 

†10.10     Ocean bio-Chem, Inc. Omnibus Equity Compensation Plan (incorporated by reference to Exhibit 99.1 to the Company’s Registration 

Statement on Form S-8, filed with the Securities and Exchange Commission on June 2, 2011).    

10.11      Net Lease dated May 1, 1998 between Star Brite Distributing, Inc. and PEJE, Inc (incorporated by reference to Exhibit 10.14 to the 

Company’s Annual Report on Form 10-K for the year ended December 31, 2004). 

10.12      Renewal of Lease dated May 1, 2008 between Star Brite Distributing, Inc. and PEJE, Inc. (incorporated by reference to Exhibit 10.24 

to the Company’s Annual Report on Form 10-K for the year ended December 31, 2008). 

10.13      OdorStar Technology, LLC Operating Agreement dated May 4, 2010 (incorporated by reference to Exhibit 10.17 to the Company’s 

Annual Report on Form 10-K for the year ended December 31, 2010). 

List o          List of Subsidiaries 
*21. 

12 

 
 
 
  
  
  
  
    
  
                                                                
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                  Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act. 
                  Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act. 

Exhibit      
No. 
*31.1     
*31.2     
*32.1     Certification of Chief Executive Officer pursuant to Rule 13a-14(b) under the Exchange Act and 18 U.S.C. Section 1350. 
*32.2     Certification of Chief Financial Officer pursuant to Rule 13a-14(b) under the Exchange Act and 18 U.S.C. Section 1350. 
101 

   The following materials from Ocean Bio-Chem Inc.’s Annual Report on Form 10-K for the year ended December 31, 2012, formatted 
in XBLR (eXtensible Business Reporting Language):  (i) Consolidated Balance Sheets at December 31, 2012 and December 31, 2011; 
(ii)  Consolidated  Statements  of  Operations  for  the  years  ended  December 31,  2012  and  2011;  (iii)  Consolidated  Statements  of 
Comprehensive  Income  for  the  years  ended  December 31,  2012  and  2011; (iv)  Consolidated  Statements  of  Changes  in  Shareholders 
Equity for the years ended December 31, 2012 and 2011, (v) Consolidated Statements of Cash Flows for the years ended December 31, 
2012 and 2011 and (vi) Notes to Consolidated Financial Statements. 

*      Filed herewith. 
†      Constitutes management contract or compensatory plan or arrangement required to be filed as in exhibit to this report. 

13 

   
 
     
   
      
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Pursuant to the requirements  of Section 13 or 15(d) of the Securities Exchange  Act of  1934, the Registrant has duly caused  this report to be 
signed on its behalf by the undersigned, thereunto duly authorized. 

SIGNATURES 

Date: April 1, 2013 

OCEAN BIO-CHEM, INC. 
Registrant 

By: /s/ Peter G. Dornau      
    PETER G. DORNAU 
    Chairman of the Board, President and 
    Chief Executive Officer 

(Principal Executive Officer) 

Pursuant  to  the  requirements  of  the  Securities  Exchange  Act  of  1934,  this  report  has  been  signed  by  the  following  persons  on  behalf  of  the 
Registrant and in the capacities and on the dates indicated. 

Signature 

    Capacity 

    Date 

 /s/ Peter G. Dornau 
Peter G. Dornau 

    Chairman of the Board, President and 
    Chief Executive Officer 
    (Principal Executive Officer) 

April 1, 2013 

 /s/Jeffrey S. Barocas 
Jeffrey S. Barocas                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

    Vice President, Chief Financial Officer 
    (Principal Financial and Accounting Officer)         

April 1, 2013 

 /s/ Gregor M. Dornau                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
Gregor M. Dornau 

April 1, 2013 

    Director 

 /s/ William W. Dudman 
William W. Dudman 

 /s/ James M. Kolisch 
James M. Kolisch 

 /s/ John B. Turner 
John B. Turner 

 /s/ Sonia B. Beard 
Sonia B. Beard 

 /s/ Diana Mazuelos Conard 
Diana Mazuelos Conard 

    Director 

    Director 

    Director 

    Director 

    Director 

April 1, 2013 

April 1, 2013 

April 1, 2013 

April 1, 2013 

April 1, 2013 

14 

  
 
  
   
   
   
   
   
   
   
   
   
   
  
  
   
       
       
   
       
   
       
   
       
       
   
   
       
       
   
       
       
   
       
       
   
       
       
   
       
       
   
       
       
   
       
       
   
       
       
   
       
       
   
       
       
   
       
       
   
       
       
  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
OCEAN BIO-CHEM, INC. AND SUBSIDIARIES 
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS 

Report of independent registered public accounting firm  

Consolidated balance sheets  

Consolidated statements of operations  

Consolidated statements of comprehensive income  

Consolidated statements of changes in shareholders’ equity  

Consolidated statements of cash flows  

Notes to consolidated financial statements  

Page 
F-2 

F-3 

F-4 

F-5 

F-6 

F-7 

     F-8 - F-17    

 
  
  
   
  
  
    
  
   
    
  
  
    
  
   
    
  
  
    
  
   
    
  
  
    
  
   
    
  
  
    
  
   
    
  
  
    
  
   
    
  
  
  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 

To the Board of Directors and Shareholders of 
Ocean Bio-Chem, Inc. and Subsidiaries 

We have audited the accompanying consolidated balance sheets of Ocean Bio-Chem, Inc. and Subsidiaries as of December 31, 2012 and 2011 
and the related consolidated statements of operations, comprehensive income, changes in shareholders’ equity, and cash flows  for each of the 
years  in  the  two-year  period  ended  December  31,  2012.  Ocean  Bio-Chem,  Inc.  and  Subsidiaries’  management  is  responsible  for  these 
consolidated financial statements. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. 

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards 
require  that  we  plan  and  perform  the  audit  to  obtain  reasonable  assurance  about  whether  the  financial  statements  are  free  of  material 
misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. 
Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the 
circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. 
Accordingly, we express no such opinion. An audit also includes examining on a test basis, evidence supporting the amounts and disclosures in 
the  consolidated  financial  statements,  assessing  the  accounting  principles  used  and  significant  estimates  made  by  management,  as  well  as 
evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. 

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position 
of Ocean Bio-Chem, Inc. and Subsidiaries as of December 31, 2012 and 2011, and the results of its operations and its cash flows for each of the 
years  in  the  two-year  period  ended  December  31,  2012,  in  conformity  with  accounting  principles  generally  accepted  in  the  United  States  of 
America. 

/s/ Goldstein Schechter Koch P.A. 
Certified Public Accountants 

Hollywood, Florida 

April 1, 2013 

F-2 

   
  
 
  
  
 
  
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OCEAN BIO-CHEM, INC. AND SUBSIDIARIES 
CONSOLIDATED BALANCE SHEETS 
DECEMBER 31, 2012 AND 2011 

ASSETS 
Current Assets: 
   Cash 

       Trade accounts receivable less allowances of approximately $73,000 and $75,000, respectively 

   Receivables due from affiliated companies 
   Inventories, net 
   Prepaid expenses and other current assets 
   Deferred tax asset 
      Total Current Assets 

Property, plant and equipment, net 

Other Assets: 
   Trademarks, trade names and patents, net 
   Other assets 

      Total Other Assets 
Total Assets 

LIABILITIES AND SHAREHOLDERS' EQUITY 
Current Liabilities: 
   Accounts payable – trade 
   Revolving line of credit 
   Current portion of long-term debt 
   Income taxes payable 
   Accrued expenses payable 
       Total Current Liabilities 

   Deferred tax liability 
   Long-term debt, less current portion 
Total Liabilities 

Commitments and contingencies 
Shareholders' Equity: 

       Common stock - $.01 par value, 12,000,000 shares authorized; 8,749,888 and 8,458,389  
       shares issued,  respectively 
   Additional paid in capital 

       Less cost of common stock in treasury, 351,503 shares 

   Foreign currency translation adjustment 
   Retained earnings 
Total Shareholders' Equity of Ocean Bio-Chem, Inc. 

   Noncontrolling interest 

       Total Shareholders' Equity 

Total Liabilities and Shareholders' Equity 

The accompanying notes are an integral part of these consolidated financial statements. 

F-3 

December 31, 
2012 

December 31, 
2011 

   $ 

1,508,385       $ 
2,931,479          
556,051          
9,256,589          
530,305          
56,221          
14,839,030          

585,357    
2,563,089    
495,130    
9,627,798    
424,168    
65,797 
13,761,339 

5,327,909          

5,213,333    

819,194          
24,350          

870,642    
33,442    

843,544          
21,010,483       $ 

904,084    
19,878,756    

   $ 

   $ 

1,431,457       $ 
-          
407,095          
65,944          
913,129          
2,817,625          

1,162,143    
850,000    
400,430    
353,608    
889,444    
3,655,625    

230,478          
1,532,286          
4,580,389          

250,191    
1,939,362    
5,845,178    

87,499          
8,617,081          
(288,013 )        
(261,807 )        
8,021,136          
16,175,896          

84,584    
8,163,864    
(288,013 ) 
(268,084 ) 
6,058,848    
13,751,199    

254,198          

282,379    

16,430,094          
$ 
21,010,483 

14,033,578    
19,878,756 

$ 

  
 
   
   
      
   
   
     
        
   
     
        
   
     
        
   
      
      
      
      
      
 
      
   
      
            
   
      
   
      
            
      
      
            
      
      
      
   
      
            
      
      
   
      
            
      
      
            
      
      
            
      
      
      
      
      
      
   
      
            
      
      
      
      
   
      
            
      
         
            
   
      
            
      
      
      
      
      
      
      
   
      
            
      
      
   
      
            
      
      
   
      
   
   
 
 
  
   
   
   
OCEAN BIO-CHEM, INC. AND SUBSIDIARIES 
CONSOLIDATED STATEMENTS OF OPERATIONS 
YEARS ENDED DECEMBER 31, 2012 AND 2011 

Gross sales 
Less: discounts, returns, and allowances 

Net sales 

Cost of goods sold 

Gross profit 

Operating Expenses: 

Advertising and promotion 
Selling and administrative 

Total operating expenses 

Operating income 

Other income (expense) 
       Interest (expense) 
       Other income 

Income before income taxes 

Provision for income taxes 

Net income 

Loss attributable to noncontrolling interests 
Net income attributable to Ocean Bio-Chem, Inc. 

Income per common share – basic 

Income per common share – diluted 

Weighted average shares – basic 
Weighted average shares – diluted 

The accompanying notes are an integral part of these consolidated financial statements. 

F-4 

2012 

2011 

   $  33,061,823        $  33,648,366    
1,967,303    

2,022,929           

       31,038,894            31,681,063    

       20,412,022            20,996,824    

       10,626,872            10,684,239    

2,417,745           
5,126,467           
7,544,212           

1,979,800    
4,989,846    
6,969,646    

3,082,660           

3,714,593    

(97,964 )        
4,489           

(150,142 ) 
50,499    

2,989,185           

3,614,950    

1,055,078           

1,279,892    

1,934,107           

2,335,058    

28,181           
1,962,288        $ 

57,579    
2,392,637    

0.24        $ 

0.30    

0.23        $ 

0.28    

8,229,720           
8,556,107           

7,953,329    
8,395,347    

   $ 

   $ 

   $ 

 
   
 
 
  
   
   
      
   
   
     
        
   
      
   
      
            
      
   
      
            
      
   
      
            
      
   
      
            
      
      
            
      
      
      
      
   
      
            
      
      
   
      
            
      
      
            
      
      
      
   
      
            
      
      
   
      
            
      
      
   
      
            
      
      
   
      
            
      
      
   
      
            
      
   
      
            
      
   
      
            
      
      
      
   
      
            
      
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
OCEAN BIO-CHEM, INC. AND SUBSIDIARIES 
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME 
YEARS ENDED DECEMBER 31, 2012 AND 2011 

Net Income 

Foreign currency translation adjustment 

Comprehensive income 

Comprehensive loss attributable to noncontrolling interests 

2012 

2011 

   $ 

1,934,107       $ 

2,335,058    

6,277          

3,855    

1,940,384          

2,338,913    

28,181          

57,579    

Comprehensive income attributable to Ocean Bio-Chem, Inc. 

   $ 

1,968,565       $ 

2,396,492    

The accompanying notes are an integral part of these consolidated financial statements. 

F-5 

   
 
 
 
   
   
      
   
   
     
        
   
   
      
            
      
      
   
      
            
      
      
   
      
            
      
      
   
      
            
      
   
      
            
      
   
  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OCEAN BIO-CHEM, INC. AND SUBSIDIARIES  
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY  
YEARS ENDED DECEMBER 31, 2012 AND 2011 

Common 
Stock 

Shares 

Amount 

Additional 
Paid In 
Capital 

Foreign 
Currency 
Translation 
Adjustment 

Retained 
Earnings 

Treasury 
Stock 

Non 
Controlling 
Interest 

Total 

January 1, 2011 

8,205,116 

$    82,051 

$   7,689,183 

$  (271,939) 

$   3,666,211 

$  (288,013) 

$   303,116 

$ 11,180,609 

Net Income (loss) 

Contribution from non- 
controlling partner 

Options exercised 

114,273 

1,143 

63,982 

Stock based compensation - 
Grants 

Stock based compensation –  
options 

Foreign currency 
translation adjustment 

139,000 

1,390 

331,793 

78,906 

3,855 

2,392,637 

(57,579) 

2,335,058 

36,842 

36,842 

65,125 

333,183 

78,906 

3,855 

December 31, 2011 

8,458,389 

$   84,584 

$   8,163,864 

$   (268,084) 

$   6,058,848 

$  (288,013) 

$   282,379 

14,033,578 

Net Income (loss) 

1,962,288 

(28,181) 

1,934,107 

Options exercised 

174,499 

1,745 

167,751 

Stock based compensation -  
Grants 

Stock based compensation – 
 options 

Foreign currency 
translation adjustment 

117,000 

1,170 

229,905 

55,561 

6,277 

169,496 

231,075 

55,561 

6,277 

December 31, 2012 

8,749,888 

$   87,499 

$   8,617,081 

$   (261,807) 

$   8,021,136 

$  (288,013) 

$   254,198 

$ 16,430,094 

The accompanying notes are an integral part of these consolidated financial statements 

F-6 

 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
   
 
 
 
 
 
 
 
 
 
 
   
  
OCEAN BIO-CHEM, INC. AND SUBSIDIARIES 
CONSOLIDATED STATEMENTS OF CASH FLOWS 
YEARS ENDED DECEMBER 31, 2012 AND 2011 

Cash flows from operating activities: 

Net income 
  Adjustment to reconcile net income to net cash provided by operations: 
    Depreciation and amortization 
    Deferred income taxes 
    Stock based compensation 
    Other operating noncash items 

Changes in assets and liabilities: 
    Trade accounts receivable 
    Inventories 
    Other assets 
    Prepaid expenses and other current assets 
    Receivables due from affiliated companies 
    Accounts payable and other accrued expenses 
Net cash provided by operating activities 

Cash flows from investing activities: 
    Purchases of property, plant and equipment 
    Contributions from (to) joint venture from non-controlling partner 
Net cash used in investing activities 
Cash flows from financing activities: 
    Net borrowings (repayments) under revolving line of credit 
    Repayments of notes payable related party 
    Proceeds from long-term debt 
    Payments on long-term debt 
    Proceeds from exercise of stock options 
Net cash used in financing activities 
    Effect of exchange rate on cash 
Net increase (decrease) in cash 
    Cash at beginning of period 
    Cash at end of period 

Supplemental disclosure of cash transactions: 
    Cash paid for interest during period 

    Cash paid for income taxes during period 

The accompanying notes are an integral part of these consolidated financial statements. 

2012 

2011 

   $ 

1,934,107        $ 

2,335,058    

701,569           
(10,137 )       
276,993           
15,457           

754,854    
231,040    
395,100    
(17,989 ) 

(366,645 )        
375,918           
9,092           
(106,137 )        
(60,921 )        
5,335           
2,774,631           

(307,365 ) 
(1,849,295 ) 
41,594    
(134,238 ) 
(282,394 ) 
(545,402 ) 
620,963    

(770,737 )        
-          
(770,737 )        

(472,005 ) 
36,842     
(435,163 ) 

(850,000 )        
-          
-          
(400,411 )        
169,496           
(1,080,915 )        
49           
923,028           
585,357           
1,508,385        $ 

850,000    
(471,950 ) 
2,430,000    
(3,088,320 ) 
65,125    
(215,145 ) 
(342 ) 
(29,687 ) 
615,044    
585,357    

100,995        $ 

163,716    

1,352,879        $ 

1,335,141    

   $ 

   $ 

   $ 

F-7 

 
 
   
   
      
   
     
        
   
   
     
        
   
      
            
      
      
      
      
      
   
         
            
   
      
            
      
      
      
      
      
      
      
      
   
      
            
      
      
            
      
      
      
      
      
            
      
      
      
      
      
      
      
      
      
      
      
            
      
   
      
            
      
   
  
   
 
 
 
 
 
 
 
 
 
 
 
 
   
  
OCEAN BIO-CHEM, INC. AND SUBSIDIARIES 
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 
YEARS ENDED DECEMBER 31, 2012 AND 2011 

Note 1 – Organization and summary of significant accounting policies: 

Organization  –  The  Company  was  incorporated  in  November  1973  under  the  laws  of  the  state  of  Florida  and  operates  as  a 
manufacturer and distributor of products principally  under  the Star brite® brand to the  marine, automotive, recreational vehicle, and 
outdoor power equipment aftermarkets. 

Basis of presentation – The consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, and 
a joint venture in  which the  Company  has a controlling interest.  All  significant inter-company accounts and transactions  have been 
eliminated in consolidation. Certain prior-period data have been reclassified to conform to the current period presentation. 

Revenue recognition – Revenue from product sales is recognized when persuasive evidence of a contract exists, the sales price is fixed 
and determinable, the title of goods passes to the customer, and collectability of the related receivable is probable. Reported net sales 
are  net  of  customer  prompt  pay  discounts,  contractual  allowances,  authorized  customer  returns,  consumer  rebates  and  other  sales 
incentives. 

Collectability of accounts receivable – Trade accounts receivable at December 31, 2012 and 2011 are net of allowances for doubtful 
accounts  aggregating  approximately  $73,000  and  $75,000,  respectively.  Such  amounts  are  based  on  management's  estimates  of  the 
creditworthiness  of  its  customers,  current  economic  conditions  and  other  historical  information.  For  the  years  ended  December  31, 
2012 and 2011 the Company had no net bad debt expense. 

Inventories – Inventories are  primarily composed of raw  materials and finished goods and are stated at the lower of cost, using the 
first-in, first-out method, or market. 

Shipping  and  handling  costs  –  All  shipping  and  handling  costs  incurred  by  the  Company  are  included  in  cost  of  goods  sold  in  the 
consolidated  statements  of  operations.  Shipping  and  handling  costs  totaled  approximately  $1,165,000  and  $1,174,000  for  the  years 
ended December 31, 2012 and 2011, respectively. 

Advertising and promotion expense – Advertising and promotion expense consists of advertising costs and catalog costs. Advertising 
costs are expensed in the period in  which the advertising occurs and totaled approximately $2,418,000 and $1,980,000 in 2012 and 
2011, respectively. The  Company capitalizes the direct cost of producing and distributing  its catalogs.  Capitalized catalog costs are 
amortized, once a catalog is distributed, over the expected net sales period, which is generally from one to 12 months. At December 
31, 2012 and 2011, the carrying value of capitalized catalog costs was not material. 

Property, plant and equipment – Property, plant and equipment is stated at cost, net of depreciation. Depreciation is provided over the 
estimated useful lives of the related assets using the straight-line method. 

Research  and  development  costs  –  Research  and  development  costs  are  expensed  as  incurred  and  recorded  in  selling  and 
administrative expenses in the consolidated statements of operations. The Company incurred approximately $76,000 and $58,000  of 
research and development costs for the years ended December 31, 2012 and 2011 respectively. 

Stock  based  compensation  –  The  Company  records  stock-based  compensation  in  accordance  with  the  provisions  of  Financial 
Accounting Standards Board Accounting Standards Codification (“ASC") Topic 718, "Accounting  for Stock Compensation,"  which 
establishes accounting standards for transactions in which an entity exchanges its equity instruments for goods or services. Under ASC 
Topic  718,  we  recognize  an  expense  for  the  fair  value  of  our  outstanding  stock  options  and  grants  as  they  vest,  whether  held  by 
employees or others. 

Use of estimates – The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires 
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent 
assets and liabilities at the date of the  financial  statements  and the reported amounts of  revenues and expenses during the reporting 
period. Actual results could differ from those estimates. 

Concentration  of  credit  risk;  dependence  on  major  customers  –  Financial  instruments  that  potentially  subject  the  Company  to 
concentration of credit risk consist primarily of accounts receivable. The Company’s  five  largest  unaffiliated customers represented 
approximately 49% and 51% of consolidated net revenues  for the  years ended December 31, 2012 and 2011, and 23% and 40% of 
consolidated  accounts  receivable  at  December  31, 2012  and  2011,  respectively.  The  Company  has  a  longstanding  relationship  with 
each of these entities and previously has collected all open receivable balances from these entities. The loss of any of these customers 
could have an adverse impact on the Company’s operations (see Note 11). 

F-8 

 
 
 
 
 
  
 
 
 
 
 
 
 
  
   
 
   
Concentration of cash – At various times during the year and at December 31, 2012, the Company had a concentration of cash in one 
bank  in  excess  of  prevailing  insurance  offered  through  the  Federal  Deposit  Insurance  Corporation  at  such  institution.  Management 
does not consider the excess deposits to be a significant risk. 

Fair value of financial instruments – ASC Topic 820, “Fair Value Measurements and Disclosures” defines “fair value” as the price that 
would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or 
liability in an orderly transaction between market participants on the measurement date. 

ASC  820  also  sets  forth  a  valuation  hierarchy  of  the  inputs  (assumptions  that  market  participants  would  use  in  pricing  an  asset  or 
liability) used to measure fair value. This hierarchy prioritizes the inputs into the following three levels: 

Level 1: Observable inputs that reflect unadjusted quoted prices for identical assets or liabilities traded in active markets. 

                Level 2:    Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either                                                

directly or indirectly. 
Level 3: Inputs that are generally unobservable. These inputs may be used with internally developed methodologies that                                  
result in management’s best estimate of fair value. 

The  carrying  amounts  of  the  Company’s  short-term  financial  instruments,  including  accounts  receivable,  accounts  payable,  certain 
accrued expenses, revolving  line of credit, and notes payable to related parties,  approximate their fair value due to the relatively short 
period  to  maturity  for  these  instruments.  The  fair  value  of  long-term  debt  is  based  on  current  rates  at  which  the  Company  could 
borrow funds with similar remaining maturities, and the carrying amount of the long-term debt approximates fair value. 

Impairment of long-lived assets – Potential impairments of long-lived assets are reviewed annually or when events and circumstances 
warrant  an  earlier  review.  In  accordance  with  ASC  Subtopic  360-10,  "Property,  Plant  and  Equipment  –  Overall,"  impairment  is 
determined when estimated future undiscounted cash flows associated with an asset are less than the asset’s carrying value. 

Income taxes – The Company records income taxes under the asset and liability method. The Company recognizes deferred income 
tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting and tax bases of 
assets and liabilities. These differences are measured using tax rates that are expected to apply to taxable income in the years in which 
those  temporary  differences  are  recovered  or  settled.  We  recognize  the  effect  on  deferred  income  taxes  of  a  change  in  tax  rates  in 
income in the period that includes the enactment date. 

We record a valuation allowance when necessary to reduce our deferred tax assets to the net amount that we believe is more likely than 
not to be realized. We consider all available evidence, both positive and negative, including historical levels of income, expectations 
and risks associated with estimates of future taxable income and ongoing tax planning strategies in assessing the need for a valuation 
allowance. 

We recognize tax benefits from uncertain tax positions only if we believe that it is more likely than not that the tax positions will be 
sustained on examination by the taxing authorities based on the technical merits of the positions. We establish and adjust reserves with 
respect to uncertain tax positions to address developments related to these positions, such as the closing of a tax audit, the expiration of 
a  statute  of  limitations  or  the  refinement  of  an  estimate.  The  provision  for  income  taxes  includes  the  effects  of  any  reserves  with 
respect to uncertain tax positions that are considered appropriate, as well as the related net interest and penalties. 

The Company has been audited by the Internal Revenue Service through the year ended December 31, 2009. 

F-9 

  
 
 
  
 
 
 
 
 
 
  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Trademarks, trade names and patents – The Company purchased the Star brite® trade name and trademark in 1980 for $880,000.  The 
cost  of  the  trade  mark  and  trade  name  initially  were  amortized  on  a  straight-line  basis  over  an  estimated  useful  life  of  40 
years.  Effective  January 1,  2002  and  in  accordance  with  ASC  Topic  350,  "Intangibles  –  Goodwill  and  Other,"  the  Company 
determined  that  these  intangible  assets  have  indefinite  lives  and  therefore,  the  Company  no  longer  recognizes  amortization 
expense.  The  Company  evaluates  intangible  assets  for  impairment  every  year  and  at  other  times  when  an  event  occurs  or 
circumstances change such that it is reasonably possible that an impairment may exist.  In addition, the Company’s 50% owned joint 
venture, OdorStar Technology, LLC, owns patents for a delivery system that enables the precise control of release rates of chlorine 
dioxide  (ClO2)  products  to  safely  help  prevent  and  eliminate  odors  caused  by  mold,  mildew  and  other  sources  of  unpleasant 
odors.  The Company amortizes these patents over their remaining life on a straight line basis.  The company amortized approximately 
$51,000 and $77,000 for the years ended December 31, 2012 and 2011 respectively. 

Foreign  currency  adjustments  –  Translation  adjustments  result  from  translating  the  Company’s  Canadian  subsidiary’s  financial 
statements into U.S. dollars.  The Company’s Canadian subsidiary’s functional currency is the Canadian dollar.  Assets and liabilities 
are  translated  at  exchange  rates  in  effect  at  the  balance  sheet  date.  Income  and  expenses  are  translated  at  average  exchange  rates 
during the year.  Resulting translation adjustments are included in Shareholders’ Equity and as a component of comprehensive income. 

Earnings per share – The Company computes earnings per share in accordance with the provisions of ASC Topic 260, "Earnings Per 
Share,"  which  specifies  the  computation,  presentation  and  disclosure  requirements  for  earnings  (loss)  per  share  for  entities  with 
publicly held common stock.  Basic earnings per share are computed by dividing net earnings available to common shareholders by the 
weighted  average  number  of  common  shares  outstanding  during  the  period.  Diluted  earnings  per  share  are  computed  assuming  the 
exercise  of  dilutive  stock  options  under  the  treasury  stock  method  and  the  related  income  tax  effects.  See  Note 12  -  Earnings  per 
share. 

Note 2 – Inventories: 

The composition of inventories at December 31, 2012 and 2011 are as follows: 

    Raw materials 
    Finished goods 
    Inventories, gross 

    Inventory reserves 

    Inventories, net 

   $ 

2012 
4,055,812       $ 
5,472,771          
9,528,583          

2011 
4,431,651 
5,472,850    
9,904,501    

(271,994 )       

(276,703 ) 

   $ 

9,256,589       $ 

9,627,798    

The inventory reserves shown in the table above reflect slow moving and obsolete inventory. 

The Company operates a vendor managed inventory program with one of its customers to improve the promotion of the Company's 
products.  The Company manages the inventory levels at this customer’s warehouses and recognizes revenue as the products are sold 
by  the  customer.  The  inventories  managed  at  the  customer’s  warehouses  amounted  to  approximately  $487,000  and  $570,000  at 
December 31, 2012 and 2011, respectively. 

F-10 

   
  
 
 
  
 
  
   
   
      
   
   
 
      
      
   
      
            
      
      
   
      
            
      
  
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Note 3 – Property, plant and equipment: 

The Company’s property, plant and equipment at December 31, 2012 and 2011 consisted of the following: 

Land 
Building and Improvements 
Manufacturing and warehouse equipment 
Office equipment and furniture 
Construction in process 
Leasehold improvements 
Property, plant and equipment, gross 

Less accumulated depreciation 

Property, plant and equipment, net 

  Estimated 
  Useful Life 

  30 years 
  6-20 years 
  3-5 years 

  10-15 years 

2012 

2011 

278,325        $ 

   $ 
278,325    
       4,489,377            4,445,924    
       7,982,669            7,632,398    
668,046    
32,788    
122,644    
       13,860,626            13,180,125    

738,584           
249,027           
122,644           

       8,532,717            7,966,792    

   $  5,327,909        $  5,213,333    

Depreciation  expense  for  the  years  ended  December  31,  2012  and  2011  amounted  to  approximately  $650,000  and  $678,000, 
respectively. 

Note 4 – Revolving Line of Credit: 

On  July  6,  2011,  the  Company,  together  with  its  subsidiary,  Kinpak  Inc.  (“Kinpak”),  entered  into  a  Credit  Agreement  with  Regions 
Bank  (and,  pursuant  to  an  Equipment  Finance  Addendum  to  the  Credit  Agreement,  Regions  Equipment  Finance  Corporation 
(“REFCO”)).  Under the Credit Agreement, the Company’s revolving line of credit with Regions Bank was renewed.  The terms of the 
revolving line of credit, as renewed, provide that the Company may borrow up to the lesser of (i) $6 million or (ii) a borrowing base 
equal to 80% of eligible accounts receivable plus 50% of eligible inventory.  Interest on the revolving line of credit is payable at the 30 
day LIBOR rate plus 1.74% per annum (unless the Company’s debt service coverage ratio (net profit plus taxes, interest, depreciation, 
amortization and rent expense divided by debt service plus interest) falls below 2.0 to 1, in which case the interest is payable at the 30 
day LIBOR rate plus 2.75% per annum).  In no event will the interest rate be less than 2.0% per annum.  Outstanding amounts under the 
revolving  line  of  credit  are  payable  on  demand.  If  no  demand  is  made,  the  Company  may  repay  and  reborrow  funds  from  time  to 
time.  The Company’s obligations under the revolving line of credit are secured by the Company’s accounts receivable and inventory, 
as  well as real property and equipment at Kinpak’s Montgomery,  Alabama  facility.  The Company’s obligations  under the revolving 
line  of  credit  and  the  term  loan  discussed  in  footnote  6  below  are  cross-collateralized.  Interest  on  amounts  borrowed  under  the 
revolving line of credit is payable in monthly installments on outstanding average balances, with all outstanding principal and interest 
payable on July 6, 2014.   The Credit Agreement includes financial covenants requiring a minimum debt service coverage ratio of 1.75 
to 1.00, tested on a rolling four-quarter basis, and a maximum debt to capitalization ratio (funded debt divided by the sum of total net 
worth  and  funded  debt)  of  0.75  to  1,  tested  quarterly.  At  December  31,  2012,  the  Company  was  in  compliance  with  these 
covenants.  The Company’s principal obligations under the revolving line of credit were $0 and $850,000 at December 31, 2012 and 
December 31, 2011, respectively. 

Note 5 – Accrued expenses payable 

Accrued expenses payable at December 31, 2012 and 2011 consisted of the following: 

Accrued customer promotions 
Accrued payroll, commissions, and benefits 
Other 

2012 

2011 

   $ 

431,015       $ 
188,645          
293,469          

485,730    
169,103    
234,611    

Total accrued expenses payable 

   $ 

913,129       $ 

889,444    

F-11 

  
 
 
  
   
      
        
   
   
   
      
   
   
     
      
        
   
     
      
     
      
      
     
   
     
       
            
      
   
     
       
            
      
     
  
 
  
  
 
 
  
   
   
      
   
   
     
        
   
      
      
   
      
            
      
  
   
 
 
 
 
Note 6 – Long-term debt: 

On July 6, 2011, under the Equipment Finance Addendum to the Credit Agreement,  REFCO provided to the Company a $2,430,000 
term loan with a fixed interest rate of 3.54%.  Principal and interest on the term loan are payable in equal monthly installments through 
July 6, 2017, the date the term loan matures.  The proceeds of the term loan were used to pay the Kinpak’s remaining lease obligations 
in  connection  with  the  previously  outstanding  2002  Series  of  Industrial  Development  Revenue  Bonds  issued  by  the  City  of 
Montgomery, Alabama (the “2002 Bonds”).  The 2002 Bonds were used to fund the expansion of Kinpak’s facilities and acquisition of 
related equipment.  At December 31, 2012 approximately $1,902,000 was outstanding under the term loan. 

At December 31, 2012 and December 31, 2011, the Company was obligated under various capital lease agreements covering equipment 
utilized in the Company’s operations.  The capital leases, aggregating $37,552 and $62,400 at December 31, 2012 and December 31, 
2011, respectively, have varying maturities through 2015 and carry interest rates ranging from 7% to 14%. 

The following table provides information regarding the Company’s long-term debt at December 31, 2012 and 2011: 

Current Portion 

2012 

2011 

Long-term Portion 

2012 

2011 

    Term loan 
    Capitalized equipment leases 

   $ 

389,075       $ 
18,020          

375,562       $ 
24,868          

1,512,754       $ 
19,532          

1,901,830    
37,532    

    Total long-term debt 

   $ 

407,095       $ 

400,430       $ 

1,532,286       $ 

1,939,362    

Required principal payments under these obligations are set forth below: 

Year ending December 31, 
2013 
2014 
2015 
2016 
2017 
Total 

   $ 

   $ 

407,095    
414,525    
425,657    
432,601    
259,503    
1,939,381    

Note 7 – Income taxes: 

The components of the Company’s consolidated provision for income taxes are as follows: 

Federal – current 
Federal – deferred 
State – current 
State – deferred 
Total provision for income taxes 

2012 
1,011,543        $ 
9,842          
33,398           
295          
1,055,078        $ 

2011 
1,036,816    
204,041    
12,036    
26,999    
1,279,892    

   $ 

   $ 

The reconciliation of the provision for income taxes at the statutory rate to the reported provision for income taxes is as follows: 

    Income Tax computed at statutory rate 
    State tax, net of federal benefit 
    Loss attributable to noncontrolling interest 
    Share based compensation 
    Temporary adjustments 
    Other, permanent adjustments 
    Tax credits and prior year tax adj. 

   $ 

2012 
1,016,323    
21,637    
9,581    
66,600    
15,388    
(86,666 ) 
12,215    

% 
34% 
.7% 
.3% 
2% 
.5% 
-2.9% 
.4% 

   $ 

2011 
1,229,083    
23,793    
19,577    
112,862    
184,205    
(105,805 ) 
(183,823 ) 

% 
34% 
.5% 
.5% 
3% 
5% 
-3% 
-5% 

    Provision for income taxes 

   $ 

1,055,078    

35% 

   $ 

1,279,892    

35% 

F-12 

 
 
  
  
  
   
   
      
   
   
   
      
      
      
   
   
     
        
        
        
   
      
   
      
            
            
            
      
  
 
     
   
      
      
      
      
 
 
  
   
   
      
   
      
      
      
  
 
   
   
   
   
   
  
  
      
      
  
      
      
  
      
      
  
      
      
  
      
      
  
      
      
  
   
      
         
      
         
  
  
  
   
 
   
The Company’s deferred tax asset and liability accounts consisted of the following at December 31, 2012 and 2011: 

Deferred taxes – current 

    Reserves for bad debts, inventories, and other accruals 

Depreciation of property and equipment 
Total deferred tax asset current 

Deferred taxes - non-current 
Depreciation of property and equipment  
Total deferred tax liability non-current 

Note 8 – Related party transactions: 

2012 

2011 

   $ 

   $  

120,740       $ 
(64,519)          
56,221       $  

123,000    
 (57,203 )  
65,797    

(230,478 )        
 (230,478 )     $  

 (250,191 )  
 (250,191 )  

   $  

During 2012, as in previous years, the Company sold products to companies affiliated with its Chairman, President and Chief Executive 
Officer.  The  affiliated  companies  distribute  the  products  outside  of  the  United  States  and  Canada.  The  Company  also  provides 
administrative  services  to  these  companies.  Sales  to  the  affiliated  companies  aggregated  approximately  $1,487,000  and  $1,764,000 
during  the  years  ended  December  31,  2012  and  2011,  respectively,  and  administrative  fees  aggregated  approximately  $335,000  and 
$332,000 during the years ended December 31, 2012 and 2011, respectively.  The Company had accounts receivable from the affiliated 
companies  in  connection  with  the  product  sales  and  administrative  services  aggregating  approximately  $556,000  and  $495,000  at 
December  31,  2012  and  2011,  respectively.  Transactions  with  the  affiliated  companies  were  made  in  the  ordinary  course  of  business 
While the terms of the sales to the affiliated companies differed from the terms of sale to other customers, the affiliated companies bear 
their own  warehousing, distribution, advertising, selling and marketing costs, as  well as  their own freight charges (the Company pays 
freight charges in connection with sales to its domestic customers on all but small orders).  Moreover, the Company does not pay sales 
commissions with respect to products sold to the affiliated companies.  As a result, the Company believes its profit margins with respect 
to  sales  to  the  affiliated  companies  are  similar  to  the  profit  margins  it  realizes  with  respect  to  sales  to  its  larger  domestic  customers. 
Management believes that the sales transactions did not involve more than normal credit risk or present other unfavorable features. 

A  subsidiary  of  the  Company  currently  uses  the  services  of  an  entity  that  is  owned  by  the  Chairman,  President  and  Chief  Executive 
Officer of the Company to conduct product research and development.  The Company paid the entity $42,000 for each of the years ended 
December 31, 2012 and 2011, respectively, under this arrangement. 

The Company leases office and warehouse facilities in Fort Lauderdale, Florida from an entity controlled by its Chairman, President and 
Chief Executive Officer.  The Company believes that the rental payments are below  market rates.  See Note 9 for a description of the 
lease terms. 

On  December  6,  2010,  the  Company  redeemed  a  warrant  held  by  its  Chairman,  President  and  Chief  Executive  Officer  to  purchase 
500,000 shares of its Common Stock at an exercise price of $0.836 per share.  The warrants initially were issued to him in connection 
with financing he provided to the Company in December 2005.  The aggregate redemption price of the warrant was $471,950, which was 
based on the difference between the closing price of the Company's Common Stock on December 6, 2010 and the exercise price of the 
warrant.  The  Company  issued  a  note  to  the  Chairman,  President  and  Chief  Executive  Officer  in  an  amount  equal  to  the  redemption 
price, which bore interest at the rate of 3% per annum.  On January 5, 2011, the Company paid all outstanding principal and interest on 
the note.  The redemption, which was approved by the independent directors of the Board of Directors, was effected in order to prevent 
the dilutive effect of the exercise of the warrant. 

A director of the Company is Regional Executive Vice President of an entity  from  which the  Company sources  most of its insurance 
needs  at  an  arm’s  length  competitive  basis.  During  each  of  the  years  ended  December  31,  2012  and  2011,  the  Company  paid  in 
aggregate of approximately $600,000 in insurance premiums on policies obtained through the entity. 

F-13 

  
  
   
   
      
   
     
        
   
      
   
      
            
      
      
            
      
      
  
 
  
 
  
 
  
   
 
 
 
 
 
 
 
 
 
 
 
 
Note 9 – Commitments 

The Company leases its executive offices and warehouse facilities in Fort Lauderdale, Florida from an entity controlled by its President 
and Chief Executive Officer. On May 1, 2008, the Company renewed the lease for a term of ten years. The lease requires minimu m 
base  rent  of  $94,800  and  provides  for  a  maximum  annual  2%  increase  in  subsequent  years,  although  the  entity  has  not  raised  the 
minimum rent since the Company entered into the lease agreement in 1998. Additionally, the leasing entity is entitled to reimbursement 
of all taxes, assessments, and any other expenses that arise from ownership. Each of the parties to the lease has agreed to review the 
terms  of  the  lease  every  three  years  at  the  request  of  the  other  party.  Rent  expense  under  the  lease  during  each  of  the  years  ended 
December 31, 2012 and 2011 was approximately $96,000. 

The Company leases from the Alabama State Port Authority a 1.5 acre docking facility on the Alabama River, located approximately 
eleven  miles  from  the  Company’s  Alabama  manufacturing  facility.  The  lease  expires  on  September  30,  2014,  and  requires  the 
Company to pay rent and additional expenses totaling approximately $7,800 annually. 

The following is a schedule of minimum future rentals on the Company’s non-cancelable operating leases. 

12 month period ending December 31, 
     2013 
     2014 
     2015 
     2016 
     2017 
     Thereafter 
     Total 

Note 10 - Stock options and awards: 

   $ 

   $ 

103,864    
97,985    
99,945    
101,944    
103,983    
34,889    
542,610    

On June 3, 2011, the Company’s shareholders  approved the Ocean Bio-Chem, Inc. Omnibus Equity Compensation Plan (the “Plan”). 
The Plan is designed (i) to meet the Nasdaq listing requirements, (ii) to enable compensation attributable to grants under the Plan to 
qualify for an exemption from the deduction limit under section 162(m) of the Internal Revenue Code of 1986, as amended, and the 
regulations promulgated thereunder (the “Code”) and (iii) to enable incentive stock options to meet the requirements of the Code. 

As a result of the adoption of the Plan, no further stock option grants will be made under the Company’s 2002 Non-Qualified Stock 
Option Plan, 2002 Incentive Stock Option Plan, 2007 Incentive Stock Option Plan, 2008 Non-Qualified Stock Option Plan and 2008 
Incentive Stock Option Plan. 

The  Plan  authorizes  750,000  shares  of  the  Company’s  common  stock  for  issuance,  subject  to  antidilution  adjustments  upon  the 
occurrence  of  certain  events  affecting  the  common  stock.  On  May  9,  2012,  the  Company  issued  stock  awards  under  the  Plan  to 
officers, key employees and  a consultant totaling 117,000 shares of common stock in the  aggregate. On June 3, 2011, the  Company 
issued  stock  awards  under  the  Plan  to  officers,  key  employees  and  a  consultant  totaling  139,000  shares  of  common  stock  in  the 
aggregate. At December 31, 2012, 494,000 shares remained available for future issuance under the Plan.  Compensation expense related 
to the stock awards was approximately $223,000 and $321,000 for the years ended December 31, 2012 and 2011, respectively. 

During 2012, stock options to purchase an aggregate of 302,800 shares were exercised and stock options to purchase an aggregate of 
11,500 shares expired. Following the  cancellation of an aggregate  of 128,301 shares in connection  with a net exercise feature of the 
stock options, the Company issued an aggregate of 174,499 shares. 

F-14 

  
 
 
 
 
    
    
      
      
      
      
      
 
 
 
 
 
  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The following tables provide  information at December 31, 2012 and 2011 regarding outstanding options  under the Company’s stock 
option plans as well as a grant made outside of the Company’s stock option plans.  As used in the table below, “2002 ISO” refers to the 
Company’s  2002  Incentive  Stock  Option  Plan,  “2007  ISO”  refers  to  the  Company’s  2007  Incentive  Stock  Option  Plan,  “2008  ISO” 
refers to the Company’s 2008 Incentive Stock Option Plan, “2002 NQ” refers to the Company’s 2002 Non-Qualified Stock Option Plan 
and “2008 NQ” refers to the Company’s 2008 Non-Qualified Stock Option Plan. 

December 31, 2012 

Plan 
Non Plan 
2008 ISO 
2002 NQ 
2002 NQ 
2002 NQ 
2002 NQ 
2008 NQ 
2008 NQ 

December 31, 2011 

Plan 
Non Plan 
2007 ISO 
2007 ISO 
2007 ISO 
2008 ISO 
2002 NQ 
2002 NQ 
2002 NQ 
2002 NQ 
2002 NQ 
2008 NQ 
2008 NQ 

Date 
Granted 

Options 

Outstanding        

Exercisable 
Options 

Exercise 
Price 

Expiration 
Date 

    Weighted      
Average 
Remaining 
Life 

3/25/09       
8/25/08       
6/20/03       
5/25/04       
4/3/06       
12/17/07       
1/11/09       
4/26/10       

115,000          
141,400          
30,000          
30,000          
40,000          
50,000          
50,000          
25,000          

115,000       $ 
107,680          
30,000          
30,000          
40,000          
50,000          
50,000          
25,000          

0.55    
0.97    
1.03    
1.46    
1.08    
1.32    
0.69    
2.07    

3/24/14       
8/21/13       
6/19/13       
5/24/14       
4/2/16       
12/16/17       
1/10/19       
4/25/20       

481,400          

447,680       $ 

0 .98       

1.2    
.7    
.5    
1.4    
3.3    
5.0    
6.1    
7.4    

2.4    

Date 
Granted 

Options 

Outstanding        

Exercisable 
Options 

Exercise 
Price 

Expiration 
Date 

    Weighted 
Remaining  
Life 

3/25/09       
5/17/07       
10/8/07       
12/17/07       
8/25/08       
10/22/02       
6/20/03       
5/25/04       
4/3/06       
12/17/07       
1/11/09       
4/26/10       

115,000          
136,500          
2,500          
142,600          
144,100          
30,000          
30,000          
30,000          
40,000          
50,000          
50,000          
25,000          
795,700          

115,000       $ 
106,000          
2,000          
111,300          
81,500          
30,000          
30,000          
30,000          
40,000          
50,000          
50,000          
25,000          
670,800       $ 

3/24/14       
5/16/12       
10/07/12       
12/16/12       
8/21/13       
10/21/12       
6/19/13       
5/24/14       
4/2/16       
12/16/17       
1/10/19       
4/25/20       

0.55    
1.66    
1.87    
1.32    
0.97    
1.26    
1.03    
1.46    
1.08    
1.32    
0.69    
2.07    
1.17       

2.3    
.4    
.8    
1.0    
1.7    
.8    
1.5    
2.4    
4.3    
6.0    
7.1    
8.4    
2.4    

F-15 

 
     
        
        
      
  
   
      
   
   
   
  
  
  
  
  
  
  
  
   
     
      
      
  
     
        
        
      
   
  
   
      
   
   
   
  
  
  
  
  
  
  
  
  
  
  
  
   
     
      
      
  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
  
The following table shows the number of options outstanding under each stock option plan at December 31, 2012: 

Plan 
Non Plan 
2008 ISO 
2002 NQ 
2008 NQ 
Totals 

Options 
Outstanding    
115,000    
141,400    
150,000    
75,000    
481,400    

The following table provides information relating to stock option transactions during the years ended December 31, 2012 and 2011: 

    Options outstanding beginning of the year 
    Options exercised 
    Options forfeited or expired 
    Options outstanding end of the year 
    Non plan options 
    Totals 

2012 
       Weighted 
       Average 
       Exercise 

2011 

       Weighted 
       Average 
       Exercise 

Shares 

Price 

Shares 

Price 

680,700       $ 
(302,800 )       
(11,500 )       
366,400          
115,000          
481,400       $ 

1.27          
1.46          
1.51          
1.11          
0.55          
0.98          

854,200       $ 
(158,500 )       
(15,000 )       
680,700          
115,000          
795,700       $ 

1.24    
1.05    
  1.66    
1.27    
0.55    
1.17    

Stock  options  may  be  awarded  as  part  of  compensation  to  executives,  employees,  directors  and  others,  pursuant  to  the  terms  of  the 
Company’s Omnibus Equity Compensation Plan, but no options were awarded under the plan in 2012 or 2011.  Grants of stock options 
or other equity awards are made at the discretion of the Equity Grant Committee of the Board of Directors.  Options previously were 
granted  under  the  Company’s  other  stock  option  plans.  Qualified  options  previously  granted  typically  have  a  five-year  term  with 
vesting in equal 20% increments on each anniversary of the date of grant.  Non-qualified options previously granted to outside directors 
have a 10-year term and are immediately exercisable.  The last tranche of non-qualified options previously granted terminate on April 
25, 2020.  Compensation cost recognized during the year ended December 31, 2012 and 2011 attributable to stock options amounted to 
approximately $54,000 and $74,000, respectively. 

At December 31, 2012 and 2011, there was approximately $12,000 and $68,000 of unrecognized compensation cost related to unvested 
share  based  compensation  arrangements,  which  will  be  charged  against  operations  as  the  options  vest  through  the  year  ending 
December 31, 2013. 

F-16 

 
   
      
      
      
      
      
 
 
   
   
      
   
   
   
  
      
  
   
   
   
   
  
      
  
   
   
   
  
      
  
   
   
   
      
      
      
   
      
      
      
      
      
      
  
 
  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Note 11 – Major customers: 

The Company has two major customers, with sales in excess of 10% of consolidated net revenues for each of the years ended December 31, 2012 and 
2011.  Sales to these customers represented approximately 37% and 40% of consolidated net revenues for 2012 and 2011, respectively. 

The Company’s top five unaffiliated customers represented approximately 49% and 51%, of consolidated net revenues for the years ended December 
31, 2012 and 2011, respectively, and 23% and 40% of consolidated trade accounts receivables at   December 31, 2012 and 2011, respectively.  While 
the  Company  enjoys  good  relations  with  these  customers,  the  loss  of  any  of  these  customers  could  have  an  adverse  impact  on  the  Company’s 
operations. 

Note 12 – Earnings per share: 

Basic  earnings  per  share  is  calculated  by  dividing  net  income  attributable  to  Ocean-Bio  Chem,  Inc.  by  the  weighted  average  number  of  shares 
outstanding during the reported period.  Diluted earnings per share reflect additional dilution from potential common stock issuable upon the exercise 
of  outstanding  stock  options.  The  following  table  sets  forth  the  computation  of  basic  and  diluted  earnings  per  common  share,  as  well  as  a 
reconciliation of the weighted average number of common shares outstanding to the weighted average number of shares outstanding on a diluted basis. 

Year Ended 
December 31 , 

2012 

       2011 

Earnings per common share –Basic 

Net income attributable to OBCI 

   $ 1,962,288       $ 2,392,637    

Weighted average number of common shares outstanding 

      8,229,720          7,953,329    

Earnings per common share – Basic 

   $ 

0.24       $ 

0.30    

Earnings per common share – Diluted 

Net income attributable to OBCI 

   $ 1,962,288       $ 2,392,637    

Weighted average number of common shares outstanding 

      8,229,720          7,953,329    

Effect of employee stock-based awards 

       326,387           442,018    

Weighted average number of common shares outstanding - assuming dilution       8,556,107          8,395,347    

Earnings per common share - Diluted 

   $ 

0.23       $ 

0.28    

The Company had no stock options outstanding at December 31, 2012 and 2011, respectively, that were anti-dilutive and therefore not included in the 
diluted earnings per common share calculation. 

Note 13 – Shareholders’ equity: 

On  June  8,  2012,  the  Company’s  shareholders  approved  an  amendment  to  the  Company’s  Articles  of  Incorporation  to  increase  the  Company’s 
authorized common stock, $.01 par value, from 10,000,000 shares to 12,000,000 shares and enable the Company to issue shares for such consideration 
as is permitted under the Florida Business Corporation Act. 

During  the  years  ended  December  31,  2012  and  2011,  the  Company  granted  stock  awards  of  117,000  and  139,000  shares  of  common  stock, 
respectively, to certain executives, key employees and a consultant.  Compensation expense recorded in connection with the stock awards for the years 
ended December 31, 2012 and 2011 aggregated approximately $223,000 and $321,000, respectively. 

During  2012,  certain  employees  of  the  Company  and  a  consultant  were  issued  174,499  shares  of  the  Company’s  common  stock  as  a  result  of 
exercising stock options.  The total cash received by the Company from the stock option exercises was approximately $169,500 and is reflected as paid 
in capital on the consolidated balance sheet. 

During  2011,  certain  employees  of  the  Company  and  a  consultant  were  issued  114,273  shares  of  the  Company’s  common  stock  as  a  result  of 
exercising stock options.  The total cash received by the Company from the stock option exercises was approximately $65,100 and is reflected as paid 
in capital on the consolidated balance sheet. 

Note -14 – Recent Accounting Pronouncements 

There have been no accounting pronouncements or changes in accounting pronouncements during the year ended December 31, 2012 that are expected 
to have a material impact on the Company’s financial position, results of operations or cash flows.  Accounting pronouncements that became effective 
during the year ended December 31, 2012 did not have a material impact on disclosures or on the Company’s financial position, results of operations 
or cash flows. 

F-17 

   
 
  
 
 
 
   
   
   
   
   
   
     
       
 
 
     
       
 
  
    
        
    
  
    
        
    
  
    
        
    
         
            
   
   
         
            
   
  
    
        
    
   
         
            
   
   
         
            
   
   
         
            
   
 
 
 
 
 
 
  
 
  
Exhibit 
No. 

EXHIBIT INDEX 

3.1.1    Articles of Incorporation and amendments through May 20, 1994  (incorporated by reference to Exhibit 3.1 to the Company’s Annual 

Report on Form 10-K for the year ended December 31, 2010). 

*3.1.2    Articles of Amendment to the Articles of Incorporation, as filed on June 13, 2012. 

3.2    Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the  Company’s Current Report on Form 8-K, filed with 

the Securities and Exchange Commission on December 5, 2011). 

10.1    Ocean Bio-Chem, Inc. Omnibus Equity Compensation Plan (incorporated by reference to Exhibit 99.1 to the Company’s Registration 

Statement on Form S-8 (file no. 333-174659), filed with the Securities and Exchange Commission on June 2, 2011). 

10.2    Credit Agreement, dated July 6, 2011, among the Company, Kinpak, Inc. and Regions Bank (the “Credit Agreement”) (incorporated 

by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2011). 

10.3    Equipment Finance Addendum, dated July 6, 2011, among the Company, Kinpak, Inc. and Regions Equipment Finance Corporation 
(incorporated by reference to Exhibit 10.1 to the  Company’s Quarterly Report on  Form 10-Q for the quarter ended September 30, 
2011). 

10.4    Promissory Note, dated July 6, 2011, issued by the Company to Regions Bank in connection with the revolving line of credit under 
the  Credit  Agreement  (incorporated  by  reference  to  Exhibit  99.3  to  the  Company’s  Current  Report  on  Form  8-K,  filed  with  the 
Securities and Exchange Commission on July 12, 2011). 

10.5    Promissory  Note,  dated  July  6,  2011,  issued  by  the  Company  and  Kinpak,  Inc.  to  Regions  Equipment  Finance  Corporation  in 
connection  with  the  term  loan  under  the  Credit  Agreement  (incorporated  by  reference  to  Exhibit  99.4  to  the  Company’s  Current 
Report on Form 8-K, filed with the Securities and Exchange Commission on July 12, 2011).  

10.6    Ocean  Bio-Chem,  Inc.  2002  Non-Qualified  Stock  Option  Plan,  as  amended  (incorporated  by  reference  to  Exhibit  99.2  to  the 

Company’s Registration Statement on Form S-8, filed with the Securities and Exchange Commission on August 12, 2011). 

10.7    Ocean Bio-Chem, Inc. 2008 Incentive Stock Option Plan, as amended (incorporated by reference to Exhibit 99.4 to the Company’s 

Registration Statement on Form S-8, filed with the Securities and Exchange Commission on August 12, 2011). 

10.8    Ocean  Bio-Chem,  Inc.  2008  Non-Qualified  Stock  Option  Plan,  as  amended  (incorporated  by  reference  to  Exhibit  99.5  to  the 

Company’s Registration Statement on Form S-8, filed with the Securities and Exchange Commission on August 12, 2011). 

10.9    Ocean Bio-Chem, Inc. Form of Stock Option granted to Peter G. Dornau (incorporated by reference to Exhibit 99.6 to the Company’s 

Registration Statement on Form S-8, filed with the Securities and Exchange Commission on August 12, 2011). 

10.10    Ocean bio-Chem, Inc. Omnibus Equity Compensation Plan (incorporated by reference to Exhibit 99.1 to the Company’s Registration 

Statement on Form S-8, filed with the Securities and Exchange Commission on June 2, 2011).    

10.11    Net Lease dated May 1, 1998 between Star Brite Distributing, Inc. and PEJE, Inc (incorporated by reference to Exhibit 10.14 to the 

Company’s Annual Report on Form 10-K for the year ended December 31, 2004). 

10.12    Renewal of Lease dated May 1, 2008 between Star Brite Distributing, Inc. and PEJE, Inc. (incorporated by reference to Exhibit 10.24 

to the Company’s Annual Report on Form 10-K for the year ended December 31, 2008). 

10.13    OdorStar Technology, LLC Operating Agreement dated May 4, 2010 (incorporated by reference to Exhibit 10.17 to the Company’s 

Annual Report on Form 10-K for the year ended December 31, 2010). 

List             List of subsidiaries 

*21.    

 
   
 
  
    
  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
Exhibit 
No. 

Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act. 
Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act. 

*31.1    
*31.2    
*32.1    Certification of Chief Executive Officer pursuant to Rule 13a-14(b) under the Exchange Act and 18 U.S.C. Section 1350. 
*32.2    Certification of Chief Financial Officer pursuant to Rule 13a-14(b) under the Exchange Act and 18 U.S.C. Section 1350. 

101    The  following  materials  from  Ocean  Bio-Chem  Inc.’s  Annual  Report  on  Form  10-K  for  the  year  ended  December 31,  2012, 
formatted  in  XBLR  (eXtensible  Business  Reporting  Language):  (i)  Consolidated  Balance  Sheets  at  December 31,  2012  and 
December 31, 2011; (ii) Consolidated Statements of Operations for the years ended December 31, 2012 and 2011; (iii) Consolidated 
Statements of Comprehensive Income for the years ended December 31, 2012 and 2011; (iv) Consolidated Statements of Changes in 
Shareholders  Equity  for  the  years  ended  December 31,  2012  and  2011,  (v)  Consolidated  Statements  of  Cash  Flows  for  the  years 
ended December 31, 2012 and 2011 and (vi) Notes to Consolidated Financial Statements. 

*      Filed herewith. 

   
  
      
   
      
   
      
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EXHIBIT 3.1.2 

ARTICLES OF AMENDMENT 

TO 

ARTICLES OF INCORPORATION 

OF 

OCEAN BIO-CHEM, INC. 

Pursuant to the provisions of Section 607.1006 of the Florida Business Corporation Act, the undersigned, Ocean Bio-Chem, Inc., a 

Florida corporation, by its President and Chief Executive Officer, does hereby make and execute these Articles of Amendment to its Articles of 
Incorporation:   

1. 

2. 

The name of the corporation is Ocean Bio-Chem, Inc.  

The Articles of Incorporation are amended by deleting Article III thereof in its entirety and by inserting, in lieu 
thereof, the following new Article III:   

ARTICLE III 

The aggregate number of shares that this corporation shall have authority to issue is 12,000,000 
shares of common stock, $.01 par value. 

3. 

The date of the adoption of the amendment by the shareholders of the corporation was June 8, 2012.   

4. 

The only voting group entitled to vote on the amendment was the holders of the corporation’s common stock.  The 
number of votes cast for the amendment by the holders of the common stock was sufficient for approval by that 
voting group.  

IN WITNESS WHEREOF, these Articles of Amendment to Articles of Incorporation of Ocean Bio-Chem, Inc. have been executed by 

Ocean Bio-Chem, Inc., by its President and Chief Executive Officer, this 12th day of June, 2012.   

OCEAN BIO-CHEM, INC. 

By: 

/s/ Peter G. Dornau 

Peter G. Dornau 

President and Chief Executive Officer 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EXHIBIT 21 

The following is a list of the Registrant’s subsidiaries: 

Name 

Star brite Distributing, Inc. 
Star brite Distributing Canada, Inc. 
D & S Advertising Services, Inc. 
Star brite StaPut, Inc. 
Star brite Service Centers, Inc. 
Star brite Automotive, Inc. 
Kinpak Inc. 
OdorStar Technology, LLC 

Jurisdiction 
of Organization 
Florida 
Florida 
Florida 
Florida 
Florida 
Florida 
Alabama 
Florida 

Ownership % 
100 
100 
100 
100 
100 
100 
100 
  50 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CERTIFICATION 

EXHIBIT 31.1 

I, Peter G. Dornau, certify that: 

1. 

2. 

3. 

4. 

I have reviewed this Annual Report on Form 10-K of Ocean Bio-Chem, Inc.; 

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to 
make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period 
covered by this report;  

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material 
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;  

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as 
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 
13a-15(f) and 15d-15(f)) for the registrant and have:  

a)  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our 

supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us 
by others within those entities, particularly during the period in which this report is being prepared;  

b)  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under 
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial 
statements for external purposes in accordance with generally accepted accounting principles;  

c)  Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about 

the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such 
evaluation; and  

d)  Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s 
most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is 
reasonably likely to materially affect, the registrant’s internal control over financial reporting; and    

5. 

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial 
reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent 
functions):  

a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are 
reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and  

b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s 

internal control over financial reporting.   

Dated:  April 1, 2013  

/s/ Peter G. Dornau 
Peter G. Dornau 
Chairman of the Board, President and 
Chief Executive Officer 
(Principal Executive Officer) 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I, Jeffrey S. Barocas, certify that: 

CERTIFICATION 

EXHIBIT 31.2 

1. 

2. 

3. 

4. 

I have reviewed this Annual Report on Form 10-K of Ocean Bio-Chem, Inc.; 

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to 
make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period 
covered by this report;  

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material 
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;  

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as 
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 
13a-15(f) and 15d-15(f)) for the registrant and have:  

a)  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our 

supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us 
by others within those entities, particularly during the period in which this report is being prepared;  

b)  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under 
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial 
statements for external purposes in accordance with generally accepted accounting principles;  

c)  Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about 

the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such 
evaluation; and  

d)  Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s 
most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is 
reasonably likely to materially affect, the registrant’s internal control over financial reporting; and   

5. 

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial 
reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent 
functions):  

a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are 
reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and  

b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s 

internal control over financial reporting.   

Dated:  April 1, 2013  

/s/ Jeffrey S. Barocas 
Jeffrey S. Barocas 
Vice President, Chief Financial Officer 
(Principal Financial and Accounting Officer) 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CERTIFICATION PURSUANT TO RULE 13a-14(b) 
UNDER THE SECURITIES EXCHANGE ACT AND 18 U.S.C. 1350 

EXHIBIT 32.1 

I, Peter G. Dornau, Chief Executive Officer of Ocean Bio-Chem, Inc. (the "Company"), hereby certify that, based on my knowledge:   

1. 

2. 

The Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2012 (the "Report") 
fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and 

The information contained in the Report fairly presents, in all material respects, the financial condition and 
result of operations of the Company.   

By: 

/s/ Peter G. Dornau 
Peter G. Dornau 
Chairman of the Board, President and 
Chief Executive Officer 
(Principal Executive Officer) 

Dated:  April 1, 2013 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CERTIFICATION PURSUANT TO RULE 13a-14(b) 
UNDER THE SECURITIES EXCHANGE ACT AND 18 U.S.C. 1350 

EXHIBIT 32.2 

I, Jeffrey S. Barocas, Chief Financial Officer of Ocean Bio-Chem, Inc. (the "Company"), hereby certify that, based on my knowledge:   

1. 

2. 

The Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2012 (the "Report") 
fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and 

The information contained in the Report fairly presents, in all material respects, the financial condition and 
result of operations of the Company.   

Dated:  April 1, 2013 

By: 

/s/ Jeffrey S. Barocas 
Jeffrey S. Barocas 
Vice President, Chief Financial Officer 
(Principal Financial and Accounting Officer) 

 
 
 
 
 
 
 
 
 
 
 
THIS PAGE LEFT INTENTIONALLY BLANK

INVESTOR INFORMATION
NASDAQ STOCK SYMBOL OBCI

Stock Transfer Agent
Registrar and Transfer Company 
10 Commerce Drive
Cranford, New Jersey 07016

General Counsel
Berger Singerman, LLP
350 East Las Olas Boulevard
Fort Lauderdale, Florida 33301

Auditors
Goldstein Schechter Koch, P.A.
4000 Hollywood Blvd., Suite 215 South
Hollywood, FL 33021

Reports and Publications
A free copy of the Company’s 2012 
Form 10-K filed with the Securites 
and Exchange Commission can be 
obtained upon written request to:

Corporate Relations Department
4041 SW 47th Avenue
Fort Lauderdale, Florida 33314

COMMON STOCK
MARKET INFORMATION
The following table sets forth high and low 
sales prices of the Common Stock of Company 
as reported on the NASDAQ Capital Market 
for each calendar quarter in 2012 and 2011: 

2012 

High 

Low 

  2011 
High     Low 

$2.78  $2.01  $3.93  $1.80                  

First Quarter 
Second Quarter    2.59    1.83 
  2.59    1.76 
Third Quarter 
  2.50    1.81 
Fourth Quarter 

  3.56     2.16 
  4.40  1.98                   
  2.68  1.68

OCEAN BIO-CHEM, INC.
BOARD OF DIRECTORS
Peter G. Dornau 
Chairman, President and 
Chief Executive Officer
Jeffrey S. Barocas
Sonia B. Beard*
Gregor M. Dornau
William W. Dudman
James M. Kolisch
Diana Mazuelos Conard*
John B. Turner*
* A member of audit and equity grant committees

OFFICERS OF 
OCEAN BIO-CHEM, INC.
Peter G. Dornau
President and Chief Executive Officer
Jeffrey S. Barocas
Vice President, Chief Financial Officer 
Gregor M. Dornau
Executive Vice President of Sales and Marketing 
William W. Dudman
Vice President of Operations, Corporate Secretary

OFFICERS OF STAR BRITE, INC.
Peter G. Dornau
President and Chief Executive Officer
Jeffrey S. Barocas
Chief Financial Officer
Gregor M. Dornau
Executive Vice President of Sales and Marketing 
William W. Dudman
Vice President of Operations
Marc A. Emmi 
Senior Vice President of Sales
Natalie S. Fino 
Vice President of Customer Service
George W. Lindsey, Jr.
Vice President of Marketing 
Dennis M. Torok 
Vice President of Sales

4041 SW 47th Avenue  •  Fort Lauderdale, Florida 33314
Tel:(954) 587-6280  •  (800) 327-8583  •  Fax:(954) 587-2813
WWW.OCEANBIOCHEM.COM  •  WWW.STARBRITE.COM
WWW.STARTRON.COM  •  WWW.NOS-GUARD.COM

 
 
 
 
OCEAN BIO-CHEM, INC.

BOARD OF DIRECTORS

Peter G. Dornau 

Chairman, President and 

Chief Executive Officer

Jeffrey S. Barocas

Sonia B. Beard*

Gregor M. Dornau

William W. Dudman

James M. Kolisch

Diana Mazuelos Conard*

John B. Turner*

* A member of audit and equity grant committees

OFFICERS OF 

OCEAN BIO-CHEM, INC.

Peter G. Dornau

President and Chief Executive Officer

Jeffrey S. Barocas

Vice President, Chief Financial Officer 

Gregor M. Dornau

William W. Dudman

Vice President of Operations, Corporate Secretary

OFFICERS OF STAR BRITE, INC.

Peter G. Dornau

President and Chief Executive Officer

Jeffrey S. Barocas

Chief Financial Officer

Gregor M. Dornau

William W. Dudman

Vice President of Operations

Marc A. Emmi 

Senior Vice President of Sales

Natalie S. Fino 

Vice President of Customer Service

George W. Lindsey, Jr.

Vice President of Marketing 

Dennis M. Torok 

Vice President of Sales

CORPORATE OFFICES • FORT LAUDERDALE, FLORIDA

MANUFACTURING & DISTRIBUTION FACILITIES • MONTGOMERY, ALABAMA

OCEAN BIO-CHEM, INC. MANUFACTURING CAPABILITIES

TANK FARM

Executive Vice President of Sales and Marketing 

QUALITY CONTROL

Executive Vice President of Sales and Marketing 

FILLING

DISTRIBUTION

4041 SW 47th Avenue  •  Fort Lauderdale, Florida 33314

Tel:(954) 587-6280  •  (800) 327-8583  •  Fax:(954) 587-2813

WWW.OCEANBIOCHEM.COM  •  WWW.STARBRITE.COM

WWW.STARTRON.COM  •  WWW.NOS-GUARD.COM

2
1
0
2
-
R
A

Ocean Bio-Chem, Inc.’s main manufacturing and distribution 
facility is its wholly owned subsidiary, Kinpak, Inc., located 
on a 20 acre site in Montgomery, Alabama. In addition to 
manufactoring Star brite® products, Kinpak also manufactures 
numerous items under private label programs. The facility’s 
300,000 s.f. manufacturing, blending, packing, and distribution 
center features a 500,000 gallon tank farm plus an additional 
1.2 million gallon tank farm on the Alabama River, as well as a 
fully-equipped R&D laboratory and a quality control center that 
performs quality audits for each phase of the production process.  

The plant has 300,000 gallons of blending capacity plus 
multiple blow-molding machines that produce custom PVC and 
HDPE bottles in various colors and shapes. There are ten fully-
automated high-speed liquid filling lines, pail lines, drum filling 
line, bulk load filling lines, plus grease filling lines capable of 
filling containers from 1 ounce to 55 gallons in size at speeds up 
to 120 gallons per minute.

Finished goods are secured by automatic case packers, case sealers 
and palletizers. In addition to a line of truck loading docks, the 
facility has a rail spur capable of handling 20 railcars.  Kinpak’s 
off-site facility is a five acre marine terminal on the Alabama River 
for accepting shipments of raw materials by barge. 

Star brite® and Star Tron® products are available at marine, 
automotive, power sports, outdoor power equipment and 
hardware stores, as well as at sporting goods stores, agriculture  
and RV stores worldwide. 

WWW.OCEANBIOCHEM.COM • WWW.STARBRITE.COM 
WWW.STARTRON.COM • WWW.NOS-GUARD.COM

40YEARS

973 -   2 0 1

1

3

Ocean Bio-Chem, Inc. 4041 S.W. 47th Ave., Ft. Lauderdale, FL 33314
T: (954) 587-6280 • Toll Free (800) 327-8583 • F: (954) 587-2813
WWW.OCEANBIOCHEM.COM • WWW.STARBRITE.COM • WWW.STARTRON.COM